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Emerging viruses in organ transplant recipients   
Immune responses to H1N1/09 influenza vaccine and hepatitis E virus 
infection 
Marie Felldin 
Department of Molecular and Clinical Medicine/Nephrology, Institute of Medicine, 
Sahlgrenska Academy at the University of Gothenburg, Sweden 
ABSTRACT 
Solid organ transplant (SOT) recipients run the risk of serious infections. The 
pandemic influenza A H1N1/09 had unknown severity, so large-scale vaccination was 
needed. The AS03-adjuvanted vaccine (PandemrixÒ) had unknown effects among 
SOT recipients. We aimed to explore the influenza-antibody (ab) response, ab 
persistence 1 year later and response to the seasonal influenza vaccine (TIV/10) among 
adult SOT recipients. Reports of narcolepsy and possible allo-sensitisation following 
the H1N1/09 vaccination necessitated an analysis of HLA abs and further follow-up. 
80% of SOT recipients and 100% of controls had seroprotective H1N1/09 titre levels 
after 2 vaccine doses (p=0.003). A significant loss of protection after 1 year was seen 
in all subjects. TIV/10 boosted a rise in seroprotection from 47% to 71% in the SOT 
group and 63% to 100% in controls. Non-responders were more often on triple 
immunosuppression and had lower renal function. No SOT recipient developed de 
novo HLA abs, but HLA abs with new specificities were detected in some patients. No 
acute rejection was seen within 2 years after vaccination. Two had chronic rejection 
within 1 year but a lower and mixed DSA response to the vaccine. The 4th study aimed 
to investigate the prevalence of hepatitis E (HEV) IgG, IgM and HEV infection, as 
chronic infection has been reported among SOT recipients. At transplantation, the anti-
HEV IgG prevalence was significantly higher in SOT patients compared with blood 
donors, 30.6% and 16.8% respectively (p<0.0001). The patients appeared to have been 
infected at an earlier age. Two cases of de novo and 2 chronic HEV infection were 
suspected but could not be verified by HEV-RNA.  
To summarise, the AS03-adjuvanted H1N1/09 influenza vaccine was effective among 
SOT recipients but significantly less compared with controls. One third of all subjects 
lost their seroprotection after one year, but TIV/10 reproduced some of the former 
protection. No patient developed de novo HLA abs. The unexpected high prevalence 
of anti-HEV IgG among the Swedish SOT recipients highlights the possibility of 
hepatitis E as a new opportunistic infection in the immune compromised host.  
Keywords: Solid organ transplant, SOT, Hepatitis E, Influenza, H1N1, AS03 
adjuvant, HLA antibodies, DSA, rejection   
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SAMMANFATTNING PÅ SVENSKA 
Den organtransplanterade patienten med livslång immundämpande 
medicinering löper risk att drabbas av allvarliga infektionskomplikationer. Två 
aspekter av detta har studerats i denna avhandling.  
Influensavirus A H1N1/09 sommaren 2009 fick en pandemisk spridning över 
världen. Sverige beslöt att massvaccinera befolkningen. Ett nytt, relativt 
oprövat vaccin valdes (PandemrixÒ), innehållande en tillsats för starkare 
vaccinationssvar. Vaccinet var ej testat på transplanterade varför effektivitet 
och ev. följdverkningar var okända. Vi följde 82 patienter och 28 friska 
kontrollpersoner som samtliga fick 2 doser med 1 månads mellanrum av 
H1N1/09-vaccinet. Blodprov togs månad 0,1 och 2. Nivån av antikroppar mot 
H1N1/09 bestämdes med s.k. hemagglutinations-inhibitionstest (HAI). Ett år 
senar gavs en dos säsongsinfluensavaccin med en komponent av H1N1/09-
viruset (TIV/10) till 49 patienter och 11 friska. Nivån H1N1/09-antikroppar 
månad 0 och 1 mättes. Andras fynd att vaccinet hos ett fåtal givit upphov till 
nya vävnadsantikroppar (HLA-antikroppar) påkallade test av blodprov tagna 
månad 0 och 2 efter H1N1/09-vaccinationen avseende HLA-antikroppar. 
Samtidigt gjordes 5-årsuppföljning via granskning av journaler. 
80% av de transplanterade och 100% av de friska nådde infektions-skyddande 
antikroppsnivå efter 2 doser H1N1/09-vaccin (p=0,003). Antikroppsnivån 1 år 
senare var 47% respektive 63% i de båda grupperna. TIV/10 ökade 
immunsvaret till 71% respektive 100% hos patienter respektive friska. De 
transplanterade som ej fick skyddseffekt av vaccinet var i högre grad 
behandlade med fler mediciner mot avstötning och hade lägre njurfunktion. 
Ingen av de som saknade HLA-antikroppar före vaccinationen utvecklade 
HLA-antikroppar och ingen fick akut avstötning under 2 år från H1N1/09-
vaccinationen. Av de 26 som hade HLA-antikroppar före vaccinationen fick 7 
nya dito men de var ej riktade mot det transplanterade organet (donorspecifika 
antikroppar; DSA). Av de 15 med DSA vid vaccinationen fick ingen nya DSA 
men full utvärdering var ej möjlig pga. äldre donatorsdata. Två 
diagnosticerades med kronisk avstötning inom ett år från vaccinationen men 
hade lägre respektive blandad styrka på DSA varför samband med 
vaccinationen är mindre trolig. De njur-transplanterade med DSA vid 
studiestart hade också lägre njurfunktion och sju av nio hade förlorat sina 
njurar vid 5 år. Ingen transplanterad drabbades av narkolepsi, ny autoimmun 
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sjukdom men en person fick plötslig dövhet ena örat efter första 
vaccinationsdosen. 
Hepatit E virus (HEV) orsakar en infektion i levern, diarré och feber liknande 
Hepatit A. HEV har ansetts ofarlig då infektionen går över av sig själv och 
endast ett fåtal fall rapporteras per år i Sverige. Bättre analysmetoder har 
nyligen visat att HEV är vanligare än vi trott; 16,8% av svenska blodgivare har 
antikroppar mot HEV. Nya rapporter om att HEV kan ge kronisk 
leverinflammation hos organtransplanterade, gjorde att vi ville kartlägga 
förekomsten av HEV i vår patientpopulation. 
196 organtransplanterade 2008–2009 lämnade blod- och urinprov från 
transplantationen och regelbundet under 2 års uppföljning. Vid 
transplantationen hade 30,6% av patienterna antikroppar mot HEV som tecken 
på genomgången infektion jämfört med 16,8% av blodgivarna (p <0,0001). 
Ålderssambandet var starkt, ju äldre desto fler hade HEV antikroppar. I 
åldersgruppen under 50 år hade 10 transplanterade patienter HEV-antikroppar 
vilket procentuellt var fler jämfört med blodgivarna (p=0,04) men i 
åldersgruppen över 50 å var det ingen skillnad. I åldrarna >60 år hade  av 
de transplanterade och  av blodgivarna genomgången HEV. Under 
uppföljningen efter transplantationen fann vi utifrån HEV-antikroppsmönstret 
2 misstänkta fall med kronisk HEV och 2 som troligen smittades under 
uppföljningen men inga av dem hade symtom och vi kunde ej påvisa viruset 
med genetisk diagnostik (qPCR HEV-RNA).  
Sammanfattningsvis var H1N1/09 vaccinationen effektiv hos de 
transplanterade men signifikant sämre jämfört med friska. Efter 1 år hade en 
tredjedel i båda grupperna tappat sin skyddande antikroppsnivå men TIV/10 
ökade nivån något bland de transplanterade. Patienter som ej hade HLA-
antikroppar påverkades ej av H1N1/09 vaccinationen. HEV var vanligare 
bland organtransplanterade jämfört med friska, vid tiden för transplantationen 
hade nästan en tredjedel haft hepatit E. Då möjligheten finns att HEV kan ge 
kronisk infektion med sekundär organpåverkan bör alla nya fall med okänd 
leverinfektion och ev. även okänd njursjukdom testas för HEV. 
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1 INTRODUCTION   
The success of solid organ transplantation (SOT) has been hampered by serious 
infectious complications. The knowledge and treatment of opportunistic 
infections, together with the development of new immunosuppressive 
medications, has led to improvements in early graft survival, decade after 
decade. Vaccination before transplantation against   specific bacterial and viral 
agents, effective prophylaxis against opportunistic infections in the early phase 
after transplantation and the opportunity to monitor viruses, in particular using 
PCR, have opened the door to the finer tuning of the immunosuppressive 
treatment.  
For many years, yearly vaccination against seasonal influenza has been part of 
the recommended treatment for all SOT recipients, but, upon the arrival of the 
influenza A(H1N1) pandemic in the summer of 2009 (named by the WHO as 
“influenza A(H1N1)pdm09”) large-scale vaccination was also needed in the 
general population. With only a little antigen available, a new adjuvanted 
vaccine was used in Sweden, as well as in other countries. The efficacy and 
side-effects of this vaccine among SOT recipients were unknown at the start 
of the vaccination, why we decided to conduct a study of vaccine response and 
side-effects in our patient cohort. As a spin-off from this primary study, we 
conducted a second study one year later, examining the remaining serological 
memory of the pandemic vaccination and the subsequent booster effect of the 
seasonal influenza vaccine in 2010. Due to both the alarming reports of 
narcolepsy in children and young adults following the AS03-adjuvanted 
vaccine and the publication of studies indicating a higher risk of rejection than 
expected after this vaccine, we decided to analyse whether our cohort of SOT 
recipients developed HLA antibodies due to the vaccination. 
Hepatitis E virus (HEV) causes an infection, with symptoms resembling 
hepatitis A. It has been regarded as a harmless, self-limiting hepatitis in the 
industrialised world, with very few cases reported on a yearly basis. However, 
following the development of diagnostic tools with high specificity and 
sensitivity has revealed that HEV infection is far more common than 
previously thought. Moreover, chronic fatal HEV infections have been 
reported among immunocompromised patients, in particular SOT recipients in 
other European countries. We decided to study the magnitude of HEV 
infection in our SOT population. 
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1.1 Organ transplantation 
The clinical transplantation of tissue and organs started more than a century 
ago with a thyroid tissue transplantation in 1883 by the Swiss surgeon Theodor 
Kocher, who thereby restored lost organ function. Other hallmarks were when 
Alexis Carrel from France developed the surgical technique of vascular 
anastomosis in 1902 and Joseph Murray and his team at Peter Bent Brigham 
Hospital in Boston, USA, conducted the first successful kidney transplantation 
in 1954 between a pair of identical twins [1]. Kidney transplantation became 
the pathfinder in the history of organ transplantation due to the development 
of the lifesaving dialysis therapy against uraemia, the opportunity to use 
optimal kidneys from live donors and also the simplicity of monitoring organ 
function [2]. As a result, most of the pioneering work in humans began in the 
field of kidney transplantation.  
1.1.1 History of transplant immunology  
It was evident in the early years that the presence of an immunological barrier, 
studied by the British scientists Medawar and Billingham, among others, using 
skin grafts in animals [3].  They found that, the more genetically alike, the less 
the rejection and, furthermore, grafts between monozygotic twin animals were 
not rejected at all. 
Of the two main immunological barriers against transplantation, the blood 
group antigen, ABO system, was discovered back in 1901 by Karl Landsteiner, 
but the importance of respecting the blood group barrier in organ 
transplantation to avoid hyper-acute rejection was first described in 1964 by 
Thomas E Starzl [4].  
The human leukocyte antigen (HLA) system has been discovered stepwise by 
different scientists starting in 1958 and, in the same year, anti-human leukocyte 
antibodies were discovered. One important step was the development of the 
micro cytotoxic test enabling the detection of HLA antigens and antibodies by 
Paul Terasaki in 1964 [5]. In 1969, Patel and Terasaki showed that a positive 
CDC crossmatch before transplantation led to rejection within two days in 80% 
of the recipients compared with only 4% if the crossmatch was negative [6]. 
Since then, a positive CDC crossmatch between donor lymphocytes and 
recipient sera is a contraindication to transplantation in all organ 
transplantation except liver transplantation. It was also found that, the better 
the HLA match, the better the graft survival and the transplant community 
8
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prioritised a full HLA match. However, in 1971, when Terasaki reported that 
there was no great difference in graft survival between one or more HLA 
mismatches [7], strict HLA matching in organ transplantation was slowly 
abandoned. Only HLA-identical siblings did better.    
1.1.2 History of immunsuppression  
In 1951, Billingham and Medawar found the prolonged survival of skin grafts 
when the animals were treated with cortisone [8]. However, the first 
immunosuppression used in clinical transplantation between dizygotic twins 
or more distantly related persons was sub-lethal total body irradiation, but this 
had to be abandoned due to the development of bone marrow aplasia and death 
from severe infections. In the late 1950s, cytotoxic drugs were developed to 
treat malignancies, but 6-mercaptopurine and its analogue, azathioprine, were 
also introduced in organ transplantation in 1960, but graft and patient survival 
were still very poor. A milestone was reached when Thomas Starzl et al. used 
concomitant prednisone therapy, resulting in prolonged kidney graft survival 
in 1963 [9]. This led to the start of several new kidney transplantation centres 
in the western world. By the end of the 1970s, the lesson of using steroids in 
lower doses was learned and the one-year graft and patient survival was 60% 
and 90% respectively after kidney transplantation. The first successful liver 
transplantation was performed in 1967, but multiple technical and 
physiological difficulties resulted in a high mortality rate. During the 
pioneering years, it was evident that the liver is a more tolerogenic organ 
compared with other whole organs, as a number of recipients survived without 
immunosuppression [2]. The first heart transplant was performed in South 
Africa by Christian Bernard in 1967 and it attracted enormous publicity 
worldwide, while the first successful lung transplant took place in 1981. In the 
late 1970s, a new drug was developed that would move the field of organ 
transplantation another step forward – cyclosporine A. This drug, when used 
in lesser nephrotoxic doses, led to significantly better graft survival in all organ 
transplantation and heralded the start of other whole organ transplantation 
programmes. In the early 1990s, tacrolimus was introduced, followed some 
years later by mycophenolic acid. Together with steroids, these drugs are still 
the cornerstones of organ transplantation.  
9
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1.1.3 Organ transplantation in Sweden and 
Gothenburg  
In Sweden, the first kidney transplantations were performed in Stockholm in 
1964. The year after, Lars-Erik “Charlie” Gelin started our unit at Sahlgrenska 
University Hospital. Kidney transplantation was soon also established in 
Uppsala and Malmö and together we currently perform 400-450 kidney 
transplantations every year. Here in Gothenburg, we perform almost 40% of 
Swedish renal transplantations and, in 2016, we celebrated kidney number 
6,000, while in Sweden a total of 15,062 kidney transplantations had been 
performed at the end of 2016. Liver transplantation programmes are running 
in Stockholm (since 1984) and Gothenburg (since 1985) with about equal 
numbers of transplantations every year, increasing steadily towards a total 
number of almost 200 a year. The first Swedish heart transplantation was 
performed in Gothenburg in 1984 and, today, together with Lund, about 60 
heart and 60 lung transplantations are performed on a yearly basis. The results 
for all organ transplantations have gradually improved, in particular during the 
first year after transplantation. For example, after renal transplantation in 
Gothenburg, as in most centres, the current one-year graft survival is 97%. 
Organ transplantation has thus developed during the last 50 years to become 
an important part of the treatment of end-stage organ failure. As the results 
have improved, we have been able to widen the indications and transplant 
individuals with higher burdens of co-morbidity.  The number of different 
transplants performed at Sahlgrenska University Hospital is shown in Fig 1. 
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1.2 Immune defence 
Our defence against foreign organisms and substances is composed of three 
major defence levels [10]. The first are the mechanical and chemical barriers, 
such as the skin, the acidity in the stomach and the mucus layer in the 
respiratory and gastrointestinal tract. The second level is the innate immunity 
which reacts immediately to microbes with an inflammatory response made up 
of mainly white blood cells, such as macrophages and neutrophils, which, 
together with chemical agents, act on phagocytosis and the destruction of 
microbes. The third level of defence is the adaptive immunity, consisting 
mainly of T and B lymphocytes which are activated more slowly and, after a 
maturation process, take part in the elimination of the foreign cells or 
substances (Fig 2). 
 
Figure 1. Solid organ transplantation at Sahlgrenska University Hospital since 
the start in 1965. In yellow: kidney (total no. 6,029), green: liver (1,745), red: 
heart (676), blue: lung (648). 
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1.2.1 Innate immunity 
This immediate defence reacts to danger signals such as microbes or tissue 
damage. Pattern recognition receptors (PRRs) on macrophages and their like 
recognise a repertoire of bacterial or viral molecules (called pathogen-
associated molecular patterns – PAMPs) or molecules from dying host cells 
(called damage-/danger-associated molecular patterns – DAMPs) [11], leading 
to the production of a number of pro-inflammatory mediators, such as the  
cytokines IL1 and TNFa. Complement is activated and this helps the 
recruitment of more inflammatory cells such as neutrophil granulocytes and 
macrophages in the acute phase. Prostaglandins promote vessel dilatation and 
increase vessel permeability, thereby facilitating the movement of 
inflammatory cells to the site of inflammation. The microbes are then 
phagocytosed. By opsonisation, i.e. the binding of immunoglobulin (IgG) and 
complement on the surfaces of microbes, phagocytosis is facilitated. The 
dendritic cell (DC) is less competent in phagocytosis compared with 
macrophages, but it plays an important role as a presenter of foreign pathogens 
in the form of degraded peptides on its cell surface. The dendritic cell is the 
Figure 2.  The innate and adaptive immune cells. By permission of prof Wayne 
LaMorte http://sphweb.bumc.bu. 
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most important “antigen presenting cell” (APC) and it is a link between the 
innate and adaptive immune systems. The dendritic cell engulfs the foreign 
pathogen and presents small parts/peptides on its HLA surface, enabling the 
activation of the adaptive immune system.  
1.2.2 Adaptive immunity 
The adaptive (or acquired) immune system is developed and differentiated 
during life, depending on the antigens we encounter. It consists mainly of 
lymphocytes of the T- and B-cell type, all of which have a unique and specific 
receptor on their surface recognising a specific antigen. The activation of this 
highly specific immune defence takes one to two weeks the first time it 
encounters an antigen, but a proportion of cells and antibodies remain as an 
immunological memory and, when the immune system meets the same antigen 
again, the activation is faster.  
Antigen presentation is mediated by Major Histocompatibility Complex 
(MHC) molecules found on cells surfaces. In humans, these structures are 
called human leukocyte antigen (HLA). They are a key component in the host 
immune defence, as foreign antigens (for example, viral peptides) are 
presented to T-cells by these molecules, enabling the host immune cells to 
recognise the intruder. Moreover, in the case of a transplanted organ, the host’s 
immune cells recognise the foreign donor HLA and this will also activate the 
immune system. As a result, the HLA system is responsible for the host’s 
ability to recognise cells as “self” as opposed to “non-self”. (The HLA system 
is further described in Section 1.2.7.)  
T-cells 
The T-cell receptor (TCR) consists of two proteins which have high variability, 
leading to a broad repertoire of specificities. In the thymus, T-cells mature 
through a selection process where those T-cells with non-functional TCR and 
those with TCR that is able to react to self-antigens are sorted out. The thymus 
thus teaches the immune system what is self and non-self. The T-cell harbours 
a protein cluster called CD3 (“cluster of differentiation”) in all differentiation 
stages and the mature T-cell expresses it on the surface of the cell and forms a 
part of the T-cell receptor. CD3 is used as a marker in histopathology to 
identify T-cells of all types. There are two major types of T-cell, CD8+ and 
CD4+, with different binding preferences to the APC and different effects. 
13
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CD4+ T-cells: These cells bind to cells expressing HLA Class II and they 
therefore only bind to APC. The CD4+ cells mature into two basic groups of 
cells; T-helper cells (Th) or T-regulatory cells (Treg). However, there appear 
to be a number of subsets of T-cells within each of these two main characters, 
each subset derived under the influence of different cytokines with somewhat 
different cytokine production from a mature T-cell.  Activated Th cells perform 
three major actions. Firstly, the Th cell produces cytokines like interferon 
gamma (INFg) which help the macrophage to enhance its capacity to kill the 
pathogen. Secondly, T-helper cells are essential in the B-cell proliferation 
process to mature into antibody-producing plasma cells. Thirdly, T-helper 
cells are needed to activate the CD8+, cytotoxic, T-cells. The T-helper cell 
therefore plays a central role in the activation and effect of the adaptive 
immune system. Tregs are able to control and down-regulate the adaptive 
immune response. They are recognised by the expression of the transcription 
factor, FOXP3. They suppress T-helper cell activation and also the APCs. 
Tregs are thereby able to induce tolerance towards the antigen. However, the 
circumstances under which the Treg effect will dominate the immune response 
is not known.  
CD8+ T-cells: Naïve CD8+ T-cells mature into cytotoxic T-cells and 
recognise antigens presented on HLA Class I molecules which are present on 
all nuclei-containing cells in the body. For example, a virus-infected cell will 
produce viral protein, and the cell will decompose the protein into peptides, as 
the cell does with its own proteins. The viral peptides will be presented on the 
HLA Class I molecule on its surface. CD8+ T-cells, randomly formed in the 
thymus with the specificity of the viral peptide, will recognise the peptide and 
will thereby be partly activated. The cytotoxic T-cell requires further help from 
an also activated CD4+ T-helper cell in the environment of the cytokines IL2 
and INFg. A fully activated cytotoxic T-cell is able to kill all the cells 
presenting the antigen for which it has specificity.  
B-cells  
There are different subsets of B-cells. B1 spontaneously secrete IgG and IgM 
antibodies with low affinity directed towards various carbohydrates as 
expressed by bacteria. B2 are the “conventional” B-cells which can be 
activated to become immunoglobulin-producing plasma cells. This activation 
requires a number of interactions with the T-helper cell. The B-cell surface has 
membrane-bound immunoglobulins and, when they meet their specific 
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antigen, the activation process starts and they develop receptors for the 
cytokines IL4, IL6 and IL10. These cytokines are produced by activated T-
helper cells which have met APCs presenting the same antigen. The B-cell is 
able to internalise the antigen and present a part of the antigen as a peptide on 
its HLA Class II surface. A T-helper cell with the specificity of this antigen 
interacts with the B-cell. At the same time, the T- and B-cells interact via co-
stimulatory molecules; for example, the CD40 ligand of the T-cells binds to 
the CD40 of the B-cells which enhances the activation of the B-cell. The result 
is effective B-cell stimulation to proliferate into mature, long-lived, plasma 
cells. B-cell maturation without Th-stimulation results in short-lived plasma 
cells [12]. 
The interaction between the TCR - antigen –MHC – has been named “signal 
one”. To fully activate lymphocytes, co-stimulation is needed, named “signal 
two” (exemplified for B-cells above). T-cells stimulated without co-
stimulation can result in T-cell anergy or apoptosis. Naïve T-cells express only 
few co-stimulatory receptors as CD28 and CD27 but they can be either up-
regulatory or inhibitory. A large diversity of receptors and ligands are present 
on APC, lymphocytes and also non-hematopoietic cells.  
33:45-25(:2/48-
An antibody consists of two parts, the specific antigen-binding, called “Fab” 
(F=fragment, ab= antigen binding), and   the “Fc” (F=fragment c= 
crystallisable) part defining the immunoglobulin type and biological action. 
There are four different types of immunoglobulin; IgM, IgG, IgA, IgE and IgD 
(Fig 3).  
                             
 
Figure 3. One unit of an immunoglobulin and its principal parts. “Fab”: the 
antigen specific binding site and the Fc part defining the isotype of 
immunoglobulin; IgG, IgM, IgA, IgE and IgD. Reproduced and modified by 
permission. Johan Mölne and Agnes Wold, “Inflammation” 2007 Liber förlag.  
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Monomeric IgM is the membrane-bound antibody on all naive B-cells, but, 
when secreted, it consists of five units of immunoglobulins held together by a 
J-chain. There are thought to be two types of IgM, natural/innate IgM and 
immune/adaptive IgM. Natural IgM is produced by a subtype of B-cells 
without having encountered a specific pathogen and constitutes the majority of 
circulating IgM in serum. These IgM are polyreactive and bind antigens with 
low affinity, compensated for by the 10 binding sites of antigens (Fig. 4). They 
are also complement binding and as a whole they are very effective in the 
clearance of infectious agents. The immune/adaptive IgM is produced by B-
cells in the spleen and lymph nodes after antigen exposure. Specific IgM is 
detectable five to 10 days after the start of an infection and it has been used as 
a marker of these events. IgM production usually subsides after six weeks 
when the B-cell matures, but specific IgM production sometimes lasts for five 
to six months [13].  Recently in mice, specific IgM production have been seen 
even two years after infection [12]. 
IgG is secreted by long-lived plasma cells, usually at a constant rate. It is 
antigen specific and it binds its antigens with high affinity. There are four 
subtypes of IgG; IgG1-IgG4. They differ in their complement-binding 
capacity; IgG3 > IgG1 > IgG3 and IgG4 do not bind complement at all. IgG 
production can be measured one to six weeks after the debut of illness and lasts 
for years, lifelong if the virus remains latent. 
IgA is present in serum as a monomer and is non-complement binding. IgA 
plays an important role in mucosal immunity. Plasma cells in the mucosa 
produce a dimeric IgA, two units of immunoglobulin, connected with a J-chain 
and a secretory component enabling “secretory IgA” to pass the epithelium 
into the lumen of the organ where IgA is able to neutralise infectious agents.  
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The hallmark of the adaptive immune system is its memory. There are both 
memory T- and B-cells, as well as long-lived plasma cells. The latter is the 
source of constant antibody (IgG) production. These memory cells reside 
primarily in lymphoid tissue and in the bone marrow, but they can quickly be 
recruited in conjunction with danger signals. They are re-activated at lower 
levels of their particular antigen exposure, sometimes without the need for co-
stimulation, resulting in a faster and stronger response.  
	
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Viruses are small particles, with diameters ranging from 20 to 300 nanometres, 
and consist of genetic material (DNA or RNA) surrounded by a protein shell 
called a capsid. They depend on the host cells for their metabolism and 
proliferation and overrule the normal metabolism of the host cells in favour of 
producing new viral particles. The new viruses are released by either host cell 
death or exocytosis (non-enveloped viruses) or by “budding”, where the viral 
particle uses a part of the host cell membrane to form an envelope, usually with 
the incorporation of viral receptors (enveloped virus). Some viruses are 
capable of a very rapid infectious cycle, within hours, resulting in the 
Figure 4. The different sorts of immunoglobulin molecules. IgG with 4 subtypes, 
IgM forming a pentamere and IgA forming secretory IgA, a dimer. Reproduced 
and modified by permission. Johan Mölne and Agnes Wold, “Inflammation” 2007 
Liber förlag  
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production of 1011 new virions within a day – an enormous amount, 
considering that humans are composed of about 1014 cells [14].  
The immune response to a viral infection is a combination of the innate and 
adaptive immune system. First, the innate system is triggered by the viral 
presence leading to the release of interferons which inhibit (or “interfere” with) 
the virus replication as INFb, INFa or IL1. INF, in turn, activates “natural 
killer cells” (NK cells).  
NK cells are classified as lymphocytes, but they lack the T-cell receptor-CD3 
complex and are members of the innate immunity (Fig. 2). Activated NK cells 
produce cytokines, mainly INFg, but they are also cytotoxic. They target cells 
lacking the MHC complex, which explains why NK cells selectively kill 
stressed cells with down-regulated MHC, such as virus-infected or 
mutated/malignant cells. When the INF/cytokine level becomes high, this 
triggers an acute-phase reaction with corresponding clinical symptoms, such 
as fever and others depending on the site of infection and, at this stage, the liver 
has shifted production from serum albumin to c-reactive protein and other 
acute-phase reactants. Dendritic cells in the lymphoid tissue in the mucosa and 
lymph nodes present viral antigen to T-lymphocytes, starting the activation of 
the adaptive immune system. B-lymphocytes are activated and mucosal IgA, 
then IgM and finally IgG production is started. As a memory of the viral 
infection, IgG persists, often lifelong, but sometimes also both TCD8+ and TCD4+ 
cells. 
1.2.4 History of vaccination 
The first attempts at vaccination appear to have taken place in China more than 
1,000 years ago. Small droplets from a smallpox virus (variola virus) pustule 
were rubbed into small scars in the skin of a healthy person to cause an 
intentional yet low-grade infection with the aim of protecting this person from 
subsequent lethal disease [14]. The technique was called “variolation”. 
Although some individuals nonetheless developed generalised disease, 
variolation slowly spread through the world. In 1796, Edward Jenner found 
that persons infected with cowpox virus developed a similar yet milder 
infection compared with smallpox and were subsequently immune to smallpox 
infection. When he used cowpox virus in variolation, the method turned out to 
be much safer, with a good protection rate. This was the first vaccine, the term 
coming from the Latin word vacca = cow.  
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1.2.5 Viral vaccines and their immunology  
Today, two major types of vaccine are used; live-attenuated vaccines, such as 
measles, mumps and rubella vaccine, where there is a possibility of viral 
replication, particularly in the immune-compromised host. For this reason, 
these are not used after organ transplantation. Secondly, inactivated vaccines 
with no potential replication, such as the first generation of influenza vaccine. 
More recently, subunit vaccines (trivalent influenza, hepatitis A and B 
vaccines) and virus-like particles (like HPV vaccine) have been developed and 
other techniques are in the pipeline [14]. 
The immunological reaction after vaccination depends on many factors, such 
as the virus properties, choice of antigen and route of administration. Most 
vaccines today are used as prophylaxis against acute viral infections which 
entails a risk of severe complications or long-term complications (such as 
cancer). The purpose of these vaccinations is to evoke a good immunological 
memory, if possible both humoral and cellular, and/or mucosal immunity. The 
protection should be long lasting, at best lifelong. The vaccination must have 
minimal side-effects and no negative long-term effects. It should preferably 
also involve a simple administration regimen and cost effectiveness [15].   
Vaccine-induced memory 
Specific antibodies against the virus are the key effector mechanism in viral 
disease protection by neutralising the viruses. This has been shown by the 
protection effect of passively administered antiviral antibodies, exemplified by 
the prophylactic treatment to prevent hepatitis B [14]. The vaccine antigen 
stimulates B-cells to produce antigen specific antibodies as a primary response 
to the vaccine. The serum concentration will gradually rise reaching a 
maximum at about 14 days. Gradually the immunoglobulin concentration will 
fall but memory B-cells will remain dormant long term. Repeated vaccine 
doses produce stimulation towards a faster and more specific IgG production 
with higher affinity (Fig5). Vaccines capable of stimulating INFg production 
will increase the immunoglobulin production of subclasses IgG1 and IgG3 
which are complement binding, further promoting the neutralising capacity. 
Hence, these repeated immunisations (booster doses) can improve the breadth 
of the immunisation by recruiting antibodies against different regions of the 
viral structure, for example, regular influenza vaccination. 
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Virus-specific IgG are, however, seldom sufficient by themselves to provide 
full protection from the viral disease. Vaccination also induces an 
accompanying T-cell memory, both T-helper cells and cytotoxic T-cells.  The 
cell-mediated memory is needed for better protection of the host from future 
infections  [16].  
*0:;'498
Adjuvants (from Latin “adjuvare” = to help) are compounds able to enhance 
or modify the immune effect of a vaccine antigen. The more refined the 
antigens used (compared with live-attenuated vaccines), the more concomitant 
antigen stimulation is needed to induce an immunological memory. Moreover, 
if fewer antigens are available or there is a need for rapid immunisation, 
adjuvant is added to the vaccine. The immunological effect of commonly used 
adjuvants has not been fully elucidated and the first adjuvants in vaccines were 
empirically derived. In the 1920s, it was recognised that, if a local 
inflammation was inflicted at the injection site, the protection provided by the 
vaccine dose was better. Further research led to the development of the first 
adjuvant vaccine used in humans containing aluminium salts (“alum”) in 1932. 
Not until 1997 was another adjuvant approved for use, “MF59”, in an influenza 
Figure 5. Serological response after repeated vaccination doses favouring a 
robust IgG secretion long term. Reproduced and modified by permission. Johan 
Mölne and Agnes Wold, “Inflammation” 2007 Liber förlag 
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vaccine formulation. MF59 is an oil-in-water emulsion composed of squalene 
oil, polysorbate and sorbitan trioleate. Squalene is a synthetic precursor of 
cholesterol and steroid hormones with normal endogenous production in 
humans of about 1g/day and it is therefore fully metabolised in the body. The 
two latter compounds are both surfactants and these three compounds form 
small oil droplets. The antigen does not adhere to the droplets, but the oil 
emulsion stimulates the innate immune cells to phagocytose and, as a result, 
antigen uptake is more efficient [17]. The enhanced protection rate among risk 
groups with tolerable side-effects was demonstrated in randomised, controlled 
studies in the late 1990s [18].  
AS03, the adjuvant in PandemrixÒ (GlaxoSmithKline, Dresden, Germany) 
used in Sweden during influenza A(H1N1)pdm09, is also an oil-in-water 
emulsion with squalene and polysorbate (surfactant), but the third component 
is alpha-tocopherol (vitamin E). The mode of action is comparable with that of 
MF59, although an even more favourable immune stimulation effect has been 
attributed to the tocopherol component [19]. This adjuvant was a more novel 
agent compared with MF59 and was less studied when the decision on vaccine 
type had to be made in the summer of 2009. AS03 was developed as an 
adjuvant to the H5N1 avian influenza pandemic vaccine, with a first human 
study published in 2007 [20]. The vaccine was further used in larger cohorts 
with a total of > 6,000 participants, showing both excellent efficacy and safety 
data [21, 22].   
 
1.2.6 Transplant immunology 
The main barriers to the acceptance of a transplanted organ are the main blood 
group type, the ABO system, and the tissue type, the HLA system.  
ABO system 
The ABO blood group system is the most important of many blood groups. 
The ABO antigens are expressed not only on erythrocytes but also by many 
epithelial and endothelial cells, such as those in the kidneys, liver. They are 
composed of a core saccharide attached to either a lipid or a protein and a 
terminal oligosaccharide. In early childhood, natural antibodies of IgG and 
IgM subtypes are developed against the A and B antigens. Individuals with 
blood group A develop antibodies against B. Individuals with blood group B 
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develop antibodies against A. Persons with blood group O (“ohne” = without) 
lacks this blood group antigen but form antibodies against both A and B, while 
persons with blood group AB have no antibodies. If the blood group barrier is 
not respected in organ transplantation, these antibodies will cause a hyper-
acute rejection. However, with immunosuppression and the removal of the 
preformed ABO antibodies, the blood group barrier is possible to overcome, 
albeit with a higher risk of early acute rejection. After a few weeks, a state of 
adaptation to the foreign blood group antigens on the graft occurs and the long-
term graft survival equals the survival of ABO compatible grafts [23]. The 
adaptation mechanism is not known. 
HLA system 
The HLA system comprises surface molecules and is essential for presentation 
of antigens for the adaptive immune system and, in the context of 
transplantation, to distinguish between cells of “self” origin or “non-self”. 
They are encoded from chromosome 6p21.3 containing some 224 genes and 
known as the most polymorphic genetic system in humans. There are two 
major classes of MHC/HLA; Class I and II.  The Class I region is most 
importantly composed of the genes encoding HLA-A, -B and –C and these 
Class I HLA structures are found on all cell surfaces except red blood cells. 
The Class II region mainly contains the genes for HLA-DR, -DQ and –DP. 
Class II are only found on APCs. To date, 12,021 HLA Class I alleles and 
4,230 Class II have been defined [24]. The genes of HLA Class I and II are 
closely linked and inherited as a haplotype in a Mendelian manner, with the 
exception of HLA-DP which has a variable inheritance. This means that 
children inherit one haplotype from their mother and one from their father. 
Among siblings, the probability of sharing one haplotype is 50%, while 25% 
of siblings are HLA -A, -B, -C, -DR, -DQ identical (“HLA identical sibling”) 
and 25% share no HLA haplotype [25].  
The tissue typing technique has evolved from cellular or serological techniques 
to molecular biological methods, all based on polymerase chain reaction (PCR) 
analyses. A description of the historical development of the different 
techniques can be found in Fig. 6. The serological tissue typing had an error 
rate of up to 20% in both Class I and Class II [26]. At our centre, PCR HLA 
typing was first used for Class II typing in 1993 and, since 2007, all HLA 
typing is done by PCR. Differences in the HLA structure between donor and 
recipients trigger the T- and B-cell immune response, as described. If a 
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recipient has HLA antibodies present before transplantation, the graft has to be 
matched with the recipient by choosing a graft which does not express those 
HLA antigens against which the HLA antibodies are directed; otherwise, there 
is a risk of rejection; the stronger the HLA antibody, the faster and more severe 
the rejection. HLA antibody formation can occur during pregnancy, blood 
transfusion or, most frequently, previous transplantation. Recipients with HLA 
antibodies are termed HLA sensitised or immunised. 
 
          
 
Detecting HLA antibodies 
Cell-based techniques: HLA antibodies are detected by either cell-based 
techniques or solid-phase techniques. Complement-dependent cytotoxic 
(CDC) crossmatch was the first technique developed in 1964 for the 
identification of HLA antibodies in the recipient [5]. By mixing donor 
 
Figure 6.  The development of HLA typing and the number of discovered antigens 
and alleles with time. Reproduced with permission, Eng HS, Leffell MS, 
Histocompatibility testing after fifty years of transplantation. Journal of 
Immunological Methods 369 (2011)1-21. 
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lymphocytes with the recipient’s serum, adding rabbit complement and finally 
a fluorescence dye, dead lymphocytes could be visualised in the fluorescence 
microscope.  Using this technique, complement-dependent and thereby strong, 
clinically significant HLA antibodies can be discovered. A positive CDC 
crossmatch is regarded as a contraindication to all organ transplantation 
(described in Section 1.2.2.), with the exception of liver transplantation [6]. 
However, the CDC technique will not detect antibodies which are complement 
independent (subtype IgG4), weaker complement activator (subtype IgG2) or 
antibodies present in lower levels. A more sensitive cell-based crossmatch 
technique was developed using flow cytometry for detection (flow, FACS or 
FC crossmatch). Donor lymphocytes are mixed with the recipient’s sera, 
together with fluoresceinated anti-human globulin, enabling HLA antibody 
detection by flow cytometry. The use and interpretation of flow crossmatch 
results have been centre specific; some centres have regarded a positive result 
as a contraindication to kidney transplantation, while others – like our centre – 
have regarded a positive result as a risk factor for rejection with a need for a 
higher immunosuppression level. Both CDC and cell-based flow crossmatches 
are not specific to HLA antibodies and can be positive, due to auto-antibodies 
or therapeutic antibodies, such as rituximab and antithymocyte globulin 
(ATG). 
Solid-phase technique: In many ways, the modern solid-phase technology for 
HLA antibody detection is a precise way to determine both the type and 
strength of the antibodies. There are a few different commercially available 
tests, but, as the Luminex platform from OneLamda, developed by Paul 
Terasaki, is the most commonly used, including at our centre, I have focused 
on this technique. A solid matrix, here polystyrene microbeads, is coated with 
purified HLA antigens and incubated with the patient’s sera. The antigen-
antibody binding is detected by anti-human IgG (or IgM, if chosen) marked 
with fluorochromes identified in the Luminex fluorometer, a flow cytometer.  
For screening purposes, multiple HLA antigens grouped into Class I and II are 
coupled with the beads and the result is positive or negative, depending on 
whether or not HLA antibodies are present (LABScreen Mixed®). A positive 
result is most often further analysed for the detection of single, specific HLA 
antigens. The beads are then coated with single HLA antigens, the 100 most 
common, enabling the detection of the specificity of the HLA antibody (single-
antigen assay). The number of antibodies is measured as the “mean 
fluorescence intensity” (MFI). The test is semi-quantitative, evaluating the 
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relative antibody strength, and there is no linear relationship between the mfi 
value and number of antibodies. Using this technique, it is possible to detect 
very low numbers of HLA IgG antibodies.  
However, the method is also associated with some difficulties. Different 
laboratories and centres have chosen different cut-off levels at which to 
consider an HLA antibody as clinically relevant. Our centre, like many, regards 
a value of ³ 1,000 MFI as a positive finding, but others have chosen 500 or 
even 2,000 MFI as a cut-off. Rare antibodies might be missed using this 
technique. In broadly sensitised patients, it might be difficult to identify single 
antibodies. Lot-to-lot differences have been reported and, due to the somewhat 
complicated laboratory handling of the test, day-to-day differences have been 
seen, all influencing the outcome of the test [27].  
Panel-reactive antibodies (PRA): both cell-based (CDC) and solid-phase 
techniques are used to screen whether the recipients have HLA antibodies 
before they are accepted for transplantation. With the CDC technique, T- and 
B-lymphocytes are tested separately. With a panel of lymphocytes derived 
from 20-30 previously HLA-typed healthy individuals, selected to represent a 
broad variety of HLA antigens, PRA is measured. The T-cells express Class I 
antigens and the B-cells both Class I and II antigens. The breath of the patient’s 
HLA antibody repertoire is given as a percentage of positive reactions of the 
total cell panel, but neither the titre nor the strength is measured.  
Matching: in kidney transplantation in particular, donor and recipient 
matching has a proven effect on graft outcome. For many years, HLA matching 
has only been regarded and calculated by the HLA-A, B- and DR-loci and, as 
most people have two of each (if not homozygote at any loci), the maximum 
mismatch is 4/2 and the minimal 0/0 (Class I/Class II respectively). However, 
the Class I locus HLA-C and the Class II loci -DQ and -DP are currently also 
possible to determine with accuracy, when evaluating both a recipient and a 
donor. A known tissue type of the donor, together with the single antigen-
determined specificity of the recipient’s HLA antibodies, make a virtual 
crossmatch possible. As a result, HLA antibodies against the prospective 
donor (donor-specific antibodies, DSA) can be evaluated even before blood 
samples are taken and a subsequent crossmatch is made. Only DSA of HLA 
origin will be accounted for, non-HLA DSA will not be discovered. These 
antibodies are rare and will not be further discussed. Different transplant 
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centres and organ procurement organisations throughout the world have 
different policies for allocating and matching kidneys.  
In Gothenburg, historically, renal recipients on the waiting list with HLA 
antibodies demonstrable with the CDC-PRA technique have been prioritised 
in allocation to crossmatch-negative donor kidneys, as it is difficult to find a 
crossmatch-negative kidney for an HLA-immunised patient. HLA antibodies 
only detectable with the solid-phase technique and also FC-crossmatch 
positivity have been disregarded. It is currently possible to make an extensive 
immunological evaluation of living and sometimes also diseased donor 
kidneys pre-transplant, in order to transplant at the lowest possible 
immunological risk by avoiding significant DSA.   
1.2.7 Rejection 
Rejection is an immunological phenomenon, involving all the mentioned 
components of both the innate and adaptive immune defence [25]. The 
rejection can be categorised depending on when it occurs after transplantation. 
Hyperacute rejection occurs minutes or hours after transplantation, due to 
preformed HLA or ABO antibodies against the donor organ. The antibodies 
are complement binding and bind to antigens on the endothelium, causing cell 
lysis and a clotting cascade, resulting in thrombosis and graft loss. This type 
of rejection is prevented by avoiding positive CDC crossmatch and respecting 
the ABO blood group barrier when choosing a graft for each recipient. Acute 
rejection is, by definition, seen days or weeks after transplantation, but it can 
occur later if the immunosuppressive treatment is suddenly lowered or if 
another event triggers the immune system. There is a gradual transition 
towards chronic rejection, a subsequent, slower rejection process. Nowadays, 
the distinction in time between acute and chronic rejection is often referred to 
as before or after six months post-transplantation.  
The rejection nomenclature based on the histological picture in an organ biopsy 
has been used for many years in all organ transplantation. International 
working groups within the different organ communities have developed 
rejection classifications. In kidney, pancreas and liver transplantation, the 
Banff classification is the dominant classification [28, 29]. In thoracic 
transplantation, the rejection classification originates from consensus meetings 
within the International Society for Heart and Lung Transplantation (ISHLT), 
but discussions are also held at Banff meetings. The Banff kidney classification 
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is the most well developed, with grading of inflammation/structural changes in 
all renal tissue components. The biopsy specimens must be investigated by 
light microscopy, extensive immune histochemistry and sometimes also 
electron microscopy. The Banff grading also includes HLA-antibody test 
results, if DSA are present or not and, most recently, molecular diagnostics 
(gene transcripts) have been included [28]. Among the other organs, the biopsy 
characteristics for rejection are not yet as clearly defined, but, in the latest 
publication from Banff regarding heart transplantation, it is stated that rejection 
changes in myocardial biopsies are, in principal (and not surprisingly), similar 
to those in kidneys [30]. Expanded rejection criteria are probably to be 
expected for the other organs as well. 
Cell-mediated rejection 
T-cells infiltrating the tissue, causing tubulitis and/or arteritis in the kidney, 
represent the most common type of rejection – “T-cell-mediated rejection” 
(TCMR) and this is most frequently an acute event. The process is started by 
direct allorecognition, where the T-cells have reacted to foreign donor HLA. 
In tissue samples, both TCD4+ and TCD8+ cells are seen, as well as macrophages 
(CD68+) and sometimes eosinophils. In kidney transplantation, inflammatory 
infiltrates are seen in the interstitial tissue, but, when T-cells infiltrate tubuli or 
arteries, the inflammation is scored as a relevant rejection. The amount of 
infiltrating lymphocytes corresponds to the severity of the rejection, according 
to Banff [28, 31]. TCMR of lower grades has been regarded as a reversible 
condition and is not correlated with graft loss. However, in a recent study, a 
clear relationship between previous TCMR and de-novo DSA was found [32].  
Antibody-mediated rejection 
Antibody-mediated rejection (AMR), also called “humoral rejection”, is a T-
cell-dependent process, but with varying degrees of visible TCMR in tissue 
biopsies. There are three typical hallmarks of AMR, shown in bold characters. 
The patients have donor-specific antibodies, DSA. Those who have 
preformed DSA, or who are previously sensitised to the donor antigen, are at 
highest risk of early AMR. During the course of transplantation, the 
development of de-novo DSA can occur and the AMR process can begin. In 
the tissue, acute AMR is associated with an accumulation of neutrophils and 
monocytes, such as macrophages causing acute tissue injury, most often 
microvascular inflammation. C4d, a degradation product from the 
complement activation cascade, is often but not always present, mostly 
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depending on HLA IgG-subtype involvement, whether or not there is 
complement binding. The better the complement binding capacity, the worse 
the tissue injury. International consensus on the histological AMR picture has 
been established in kidney, pancreas and heart transplantation. Acute AMR 
after liver transplantation is rare and transplantations have been performed 
regardless of pre-transplant CDC crossmatch results, with good overall results.  
There are a number of theories about why the liver is an immunologically 
protected organ; this is perhaps due to the effective clearance of immune 
complexes by Kupffer cells and/or the lower expression of HLA Class II 
antigens or other reasons [29]. In recent years, AMR in liver has been 
described, after ABO-incompatible liver transplantation and among a fraction 
of highly immunised patients, for example. These recipients have both Class I 
and in particular Class II HLA antibodies with very high MFI (>10,000). In the 
last Banff publication on AMR in liver transplantation, the present knowledge 
in this field was reviewed and a grading of AMR was published [29]. In lung 
transplantation, there is no consensus scoring system for AMR, but there are 
reports of patients with a clinical picture fulfilling the three general AMR 
criteria; DSA, C4d and microvascular inflammation [33].  
Acute vascular lesions in kidney grafts 
Vasculitis in renal grafts has been regarded as a cell-mediated rejection process 
and graded as such according to Banff. However, in recent years, isolated 
vasculitis can be seen in AMR and in delayed graft function as well [31]. 
Lefaucheur et al. found that one third of vascular rejection was due to AMR in 
a retrospective analysis of a large cohort of renal-transplanted recipients, when 
a re-evaluation of biopsies according to modern Banff criteria was made [34]. 
Not surprisingly, there is an overlap between cellular and humoral rejection 
processes, as is very clearly illustrated in Fig.7. 
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Chronic rejection 
In all organ transplantation, a clinical picture of slow yet inevitable graft failure 
is seen, even after specific causes, such as acute rejection, recurrence of 
primary disease, viral or bacterial infection or de-novo diseases, have been 
ruled out. Chronic rejection in lung transplantation has been called 
bronchiolitis obliterans syndrome (BOS), but a broader term, “Chronic Lung 
Allograft Dysfunction” (CLAD) is currently used, including both obstructive 
and restrictive patterns of progressive lung dysfunction. In heart 
transplantation, the clinical picture of “Chronic Allograft Vasculopathy” 
(CAV) with the progressive atherosclerosis of epicardial and penetrating graft 
vessels is seen on coronary angiograms. Liver transplant recipients run the risk 
of developing vanishing bile duct syndrome and, in renal transplants, 
interstitial fibrosis/tubular atrophy (IF/TA) and/or transplant glomerulopathy 
(TG) is seen [25].  
Some of the patients developing chronic rejection have a history of earlier 
acute rejection, while others have no risk factors. Nevertheless, at some time 
Figure 7.  Four different rejections patterns with a considerable overlap; 
TCMR/V- (T-cell mediated rejection/no vasculitis), TCMR/V+ (with vasculitis), 
ABMR/V- (antibody mediated rejection/no vasculitis), ABMR/V+ (with vasculitis). 
Reprinted from Lancet Vol 381 Carmen Lefaucheur, Alexandre Loupy, et al.” 
Antibody-mediated vascular rejection of kidney allografts: a population-based 
study” p313-319 (2013) with permission from Elsevier.  
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point, allorecognition occurs and a chronic inflammation begins. Activated 
macrophages produce enzymes (metalloproteinases) able to degrade tissue 
matrix proteins. These enzymes are dependent on nitric oxide for their 
activation. If the organ-specific cells in the inflammation process have lost 
their structure, they are not able to regenerate. Instead, fibroblasts replace 
them, resulting in increased collagen production. The result is the destruction 
of the tissue and loss of organ function [10].  
The histopathological findings therefore have similarities between organs, in 
particular, vascular changes with intimal hyperplasia and the proliferation of 
smooth muscle cells leading to chronic graft vasculopathy. Importantly, a 
scarring process as a result of fibroblast proliferation and collagen deposition 
replaces the original tissue [25].   
1.2.8 Immunosuppressive therapy 
The history of maintenance immunosuppression can be found in Section 1.1. 
A description of only those agents used in the studies included in this thesis, 
based mainly on these references, now follows [25, 35].  
Induction therapy 
Before transplantation, often in the operating theatre before the arterial 
circulation of the graft is started, a high dose of immunosuppression is given – 
an induction therapy – to produce an immediate knock-out of the immune 
reaction. A bolus dose of steroids (methylprednisolone) is standard therapy 
throughout the world. In later years, many centres, including ours, have added 
the anti-interleukin-2 receptor antibody (IL-2RA) basililximab (SimulectÒ) 
before renal and liver transplantation. In high-risk recipients, such as thoracic 
transplantation, highly immunised recipients and/or the risk of delayed renal 
graft function, anti-thymocyte globulin (ATG) is given in combination with 
steroids. ATG comprises purified polyclonal antibodies against human T-
lymphocytes attained by immunising rabbits or horses with human T-cells, first 
used in 1966. Rituximab, a monoclonal antibody against CD20+ B-cells, is 
standard treatment as induction before ABO-incompatible transplantation, but 
it can also be used in highly immunised recipients in whom DSA has or has 
not been detected.    
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Maintenance therapy 
The cornerstone of immunosuppression in SOT, following the introduction of 
cyclosporine A in 1983, is “triple drug therapy”. It consists of one calcineurin 
inhibitor (CNI), one anti-metabolite, together with corticosteroids.  
Calcineurin inhibitors (CNI): Cyclosporine A and tacrolimus are the 
backbone of today’s organ transplantation and, although they are different 
chemical substances, they have a very similar effect on the immune system and 
side-effects. Intracellular in T-cells, they bind to calcineurin and thereby 
impair the production of cytokines such as IL2, IL4, INFg and TNFa, resulting 
in the reduction of T-cell activation. Although they are still the most effective 
T-cell inhibitors for oral treatment, they have troublesome side-effects, the 
most prominent of which is nephrotoxicity (“CNI nephrotoxicity”). The 
mechanism is acute and reversible vasoconstriction of renal vessels, but 
continuous use leads to chronic changes, with the development of arterial 
thickening and interstitial fibrosis. This is a limiting factor in renal 
transplantation when it comes to long-term graft survival and promotes the 
development of renal failure in other organ transplant recipients. Furthermore, 
negative metabolic effects, such as hypertension, dyslipidaemia and diabetes, 
are seen. 
Antimetabolites: Azathioprine is a prodrug to 6-mercaptopurine which in turn 
inhibits DNA synthesis and thereby cell division. Nowadays, mycophenolic 
acid (MPA; mycophenolate mofetil or enteric coated mycophenolate sodium) 
is more frequently used. The drug inhibits de novo purine synthesis which is 
crucial for the proliferation of lymphocytes, while other cells often have 
salvage systems. MPA therefore has a more selective action of preventing 
proliferation in T- and B-cells. These drugs are also limited by their side-
effects, in particular bone marrow depression. 
Corticosteroids (CS) have multiple effects on the immune system and inhibit 
both innate and adaptive immune responses. For example, the lower 
production of cytokines such as TNFa, INFg, IL1, IL2, IL3 and IL6 is seen. 
Due to the multiple negative side-effects such as osteonecrosis, diabetes, 
hypertension, dyslipidaemia and weight gain after transplantation, many 
steroid-sparing protocols have been tried with a wide variety of protocols in 
different organs, albeit at the expense of more rejections [25].  
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Inhibitors of mammalian target of rapamycin (mTOR): Sirolimus and its 
derivate, everolimus, basically have a common effect pathway and side-effects. 
The specific inhibition of mTOR by the drug leads to the blockade of T-cell 
activation by arresting the cell cycle in the G1-S phase. A number of side-
effects (sometimes dose dependent) limit the use of these drugs, such as 
worsening proteinuria and hyperlipidaemia. The mTOR inhibitors also appear 
to have  anti-viral, anti-tumour and anti-fibrotic effects [36].  
Rejection therapy 
T-cell-mediated rejection (TCMR) is usually a reversible process if it is 
found in time and treated with high-dose steroids and an elevation of the 
maintenance immunosuppression. If it is steroid resistant, anti-thymocyte 
globulin (ATG) should be added.  
Antibody-mediated rejection (AMR) is difficult to treat and there is no 
consensus on what to use and how. The triad of rituximab to inhibit B-cell 
proliferation, plasma exchange to achieve HLA-antibody removal and high-
dose intravenous immunoglobulin to neutralise HLA-IgG has been used by 
many in different dosages and combinations with positive effects, particularly 
in the acute setting, but randomised, controlled trials are lacking. In the case of 
chronic AMR, evidence of any good therapy is lacking.  
1.3 Viral infections 
Due to immunosuppressive treatment, SOT recipients run a higher risk of 
infection compared with healthy individuals. Historically, opportunistic 
infections such as cytomegalovirus (CMV) or other herpes virus infections, as 
well as Pneumocystis jiroveci, caused tremendous morbidity, as well as 
significant mortality, prior to the development of antiviral medication and 
prophylactic treatment strategies. The use of more effective maintenance 
immunosuppression in renal transplantation has resulted in a higher incidence 
of BK virus nephropathy, with reduced graft function or even graft loss.  
In this thesis, the work has focused on recent, in our experience newly 
emerging, viral threats to the immunocompromised individual; the influenza 
pandemic in 2009 and the use of a not fully tested new vaccine and hepatitis 
E, known, but unrecognised, in our part of the world and in particular its 
possible effects among our SOT recipients.  
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(The basic facts in the 1.3 viral infection section have been gathered from 
textbooks [14, 15], unless otherwise stated.) 
1.4 Influenza 
1.4.1 Influenza virus characteristics 
The viruses are enveloped, single-stranded, negative-sense RNA viruses with 
a size of 80-120 nm [37]. There are three different types; influenza A, B and 
C, with different protein and genomic structures, causing different properties 
and epidemiology. Influenza A is further subdivided depending on differences 
in the two major surface glycoproteins; haemagglutinin (HA) and 
neuraminidase (NA) (Fig. 8). There are 16 different known HA types referred 
to as H1-H16 and nine NA types referred to as N1-N9. The most common 
subtypes of influenza A in humans are H1N1, H2N2 and H3N2. A large pool 
of influenza A virus is found among animals such as birds (avian influenza), 
where the subtypes H5N1 and H9N2 are often found, and among swine, H1N1 
and H3N2. Although the zoonotic influenza types share subtype designations, 
they are distinctly different from the human subtypes and rarely infect humans, 
unless there is direct contact with the animals.  
Influenza A has eight different RNA segments encoding 11 proteins and it 
undergoes continuous genetic changes. Point mutations in the RNA for HA 
and NA give rise to minor changes in these surface molecules, called antigenic 
drift. Major, epidemically important drifts are seen every two to three years.  
Influenza A is also able to acquire new gene segments, called antigenic shift, 
resulting in marked changes in the HA antigen structure. This can occur when 
cells are dually infected with both a human and an animal influenza virus and 
it gives rise to marked changes in the surface proteins, following which a new 
influenza virus is born. With no immunity in the population to the new virus 
strain, the virus is able to cause pandemic influenza (Fig 8). Antigen shifts do 
not occur in influenza B and antigen drift is much less frequent and this virus 
only gives rise to local epidemics. Influenza C is genetically stable and causes 
only sporadic, mild infections, particularly in children. 
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Immunity to influenza  
An influenza infection gives rise to long-lived immunity to the infected virus 
strain. Variable cross-protection has been seen within subtype groups. 
Infection gives rise to antibody production against both HA and NA but also 
other structural proteins. The peak antibody response after infection occurs 
after four to seven weeks, after which it slowly declines.  
The HA protein is defined by its ability to heamagglutinate red blood cells. 
Antibodies against HA have been shown to be protective against influenza 
infection. The most widely used serological assay for the determination of 
influenza protection detect these antibodies that are able to block 
haemagglutination i.e. haemagglutination-inhibiting antibody assays (HAI). 
There is some uncertainty about the HAI titre that corresponds to protection; 
1:8-1:160 but the titre 1:40 is used since very long in vaccine studies, reducing 
the infection risk 40-70% among healthy, as recently confirmed [38]. The NA 
antibody does not neutralise virus infectivity but reduces the amount of virus 
leaving the infected cell. This explains why the severity of the infection 
becomes less. Mucosal antibody production against influenza protects the 
Figure 8.  A schematic illustration of the Influenza A virus with its surface 
glycoproteins HA (haemagglutinin) and NA (neuraminidase) and 8 RNA strands. 
The different pandemic influenza viruses since 1918 are illustrated with the 
antigen shifts marked by different colours of the RNA strands. (The 1977 
Influenza has not been classified as “pandemic”).  Reprinted from Trends In 
Microbiology Vol. 20(1), Watanabe Y, Ibrahim M et al. “The changing nature of 
avian influenza A virus (H5N1)” p11-20, (2012) with permission from Elsevier. 
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individual from upper respiratory symptoms in particular. The cellular immune 
defence is less studied. CD4+ and CD8+ T-cells have been found five to 14 
days after the infection [15]. 
Seasonal influenza  
Influenza infections have a typical seasonal pattern, giving rise to infection in 
the northern hemisphere during November and April and in the southern 
hemisphere between May and September. Although an influenza infection 
gives rise to immunity, the antigen drift will change the viral antigen and the 
individual will therefore become susceptible to following seasonal variants. 
The incubation period is short, one to five days, and the virus can have a very 
rapid onset and transmission in the population [14]. 
Symptoms and health burden 
The symptoms of the influenza virus are very well known, as it gives rise to a 
respiratory infection with fever and aching muscles. However, complications 
can occur, particularly among influenza infection risk groups, defined as age 
³65 years, pregnancy >16 weeks, adults and children (>6 months) with chronic 
heart-, lung-, liver- or kidney disease, diabetes mellitus or 
immunocompromised. Primary viral pneumonia is uncommon, but it is a very 
serious condition. Bacterial superinfection is well known and the largest cause 
of morbidity and mortality after influenza. As a result, there is mortality 
associated with influenza, even among individuals not belonging to any risk 
group. Severe influenza affects three to five million individuals worldwide 
every year, as estimated by the WHO, resulting in 250,000-500,000 deaths 
[39]. In Europe, the rates are lower and depend on seasonal and current 
immunity in the population to the dominant virus strain. The 2015-2016 season 
in Sweden was dominated by influenza A(H1N1)pdm09 (in short H1N1/09). 
Our country, with close to 10 million inhabitants, had 261 deaths occurring 
within 30 days of a laboratory-confirmed influenza diagnosis, 79% were ³ 65 
years, 18% 40-64 years. Among those patients with a laboratory diagnosis, the 
mortality was 9% if ³ 65 years and 2% if 40-65 years. Of those belonging to a 
risk group who were in need of intensive care, only 11% had been vaccinated. 
Furthermore, 15 of the fatal cases did not belong to a risk group [40]. Between 
1-4% of SOT recipients are infected annually [41]. Among the SOT recipients, 
in particular lung transplanted patients are at risk of serious infection. The 
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incidence during a 10 year period in Pittsburgh was among lung transplanted 
41.8 cases/1000 persons year compared to liver 2.8 and kidney 4.3 [42].  
Seasonal vaccination 
A number of reference viral laboratories around the world report their 
individual current influenza strain isolates and number of cases (The Global 
Influenza Surveillance Network) to the WHO. The WHO analyses and predicts 
the possible upcoming seasonal virus. The upcoming seasonal influenza 
vaccine is decided on the basis of these analyses. Seasonal influenza 
vaccination saves both lives and money. In a recent European report, 180 
million persons fulfil the indication for vaccination and today about 80 million 
(44%) are vaccinated annually. If the vaccination adherence could be raised to 
75%, the European influenza work group estimates that this would save 
another 9,000-14,000 lives and would result in a total health cost saving of 
€190-226 million [39].  
The most used influenza vaccines are formalin inactivated, whole or split virus 
or purified surface antigen. Antigens for inactivated antigens are mass-
produced in embryonated chicken eggs. Seasonal vaccine is composed of three 
antigens, two influenza A and one influenza B, with a minimum antigen 
content of 15 µg each. This type of seasonal vaccine is called trivalent 
influenza vaccine (TIV).  
The immunogenicity among healthy adults who have encountered former 
influenza strains is as follows; >85% attain a protective HAI antibody response 
after TIV. A serological response can be seen after 10 days and lasts for up to 
two to three years [14]. The safety of TIV has been established by many large 
studies, the largest of which comprised 250,000 vaccinated children (< 18 
years of age). The most common adverse event is local tenderness at the 
injection site, while systemic symptoms are rare; in studies, it is equal to 
placebo. Data regarding transplant patients seroresponse to TIV differ. Some 
studies report an equal response compared with healthy [43, 44]. Most studies 
though, reports reduced seroprotection rates [45, 46]. The use of MPA and 
vaccination within six months of transplantation have been associated with 
diminished vaccine response [43, 45]. There are particular difficulties when 
analysing seasonal influenza vaccine response since the baseline 
seroprotection and reaction upon the vaccine may differ depending on the 
history of former vaccination and infections. 
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Rejection after seasonal influenza infection or TIV  
Seasonal influenza infection have in earlier years reported to coincide with the 
development of acute rejection [47]. If influenza vaccination also can elicit 
rejection has not been shown [43] although the studies mostly are small and 
have not been designed to address the question [46]. Few have studied the HLA 
reaction but TIV did not give rise to de novo HLA sensitisation or significant 
change in pre-existing HLA antibody levels among 66 stable renal transplant 
recipients [48].  
Pandemic influenza  
Although ancient text indicates the occurrence of influenza epidemics since 
antiquity, the earliest known is the “Spanish flu” of 1918, causing the death of 
50 million people (in Sweden about 35,000). This virus strain was 
subsequently isolated and confirmed as subtype H1N1. The next influenzas 
pandemics were Asian flu in 1957 (H2N2), with five million deaths worldwide, 
and Hong Kong flu in 1968 (H3N2). The definition of pandemic influenza is 
not totally clear. “Simultaneous worldwide transmission” is one.  A novel 
influenza strain with the absence of immunity in the population, combined with 
a worldwide spread of virus, is a summary of the WHO criteria. The severity 
of the disease is no longer included in the definition and this has triggered a 
debate [49, 50].  
1.4.2 Influenza A(H1N1)pdm09 
In late March 2009, reports of hospitalisation and deaths among young adults 
in Mexico due to respiratory illness was reported to the health authorities [51]. 
On 21 April 2009, two cases of a novel influenza were diagnosed in California. 
The virus spread quickly and, on 9 June, a total of 73 countries had reported 
more than 26,000 laboratory-confirmed cases. On 11 June, the WHO declared 
the first influenza pandemic since 1969 [52].  
The new virus was of the H1N1 subtype, but it had multiple antigen shifts, 
making it a new, never previously encountered type. It contained five RNA 
segments from two different and distinct swine viruses, two from birds and one 
from human influenza virus [53] (Fig. 8). A recent study confirms the origin 
as coming from the swine population in Mexico and, although new viruses 
have usually evolved in Asia, the Mexican source is explained by the 
worldwide trade in livestock [54].  
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H1N1/09 infection in healthy individuals 
The outcome among the first influenza cases in Mexico was serious. Of 899 
hospitalised cases, 6.5% became critically ill and, of those, 41% died. As the 
influenza progressed over the world, the mortality among children, young 
adults and pregnant women was higher compared with that of typical seasonal 
influenza, but the elderly did relatively well. However, there was a substantial 
difference depending on regions of the world. Estimations of deaths during the 
pandemic have been made, but they are similar to a mild seasonal flu. 
However, when counting years of life lost, the H1N1/09 influenza was worse, 
due to the high mortality among the youngest individuals [52]. In Sweden, the 
first cases were diagnosed in May 2009 and, in the beginning, mostly imported 
cases were found. In the middle of October, there were more cases and the 
infection had its peak incidence in the middle of November. In Stockholm, 
11% of confirmed cases were hospitalised and one (0.4%) died. Influenza 
disease was seen in 7% in spite of vaccination [55]. The total number of deaths 
in Sweden due to confirmed influenza H1N1/09 was 31, i.e. less compared to 
other seasons due to a lower incidence among the elderly. 
H1N1/09 infection in SOT 
A cohort study performed in North America of SOT recipients, where 26 
transplant centres reported their microbiology-confirmed cases of influenza 
H1N1/09 during April-December 2009, identified 237 cases, of which 71% 
were admitted to hospital, 16% to the ICU and 4% (n=10) died. Almost all 
were treated with oseltamivir and, of those receiving the drug within 48 hours 
after the onset of symptoms, 8% were in need of intensive care compared with 
22.4% with later introduction of the drug [56]. In a retrospective study of 
kidney-transplanted individuals in Brazil during the 2009 pandemic, the 
mortality rate was 9.1%. Since the outbreak of the infection was early during 
the pandemic, no one had received vaccination but almost all were treated with 
oseltamivir [57]. 
Pandemic vaccine 
Due to the rapid spread of the influenza pandemic and the first reports of high 
virulence among young people, a new vaccine had to be produced at short 
notice. This time not only risk groups were going to be vaccinated but also 
whole populations and there was therefore a shortage of antigen. In Sweden, 
as well as in many other European countries, the choice of vaccine fell on 
PandemrixÒ,, the monovalent, AS03-adjuvanted vaccine containing only 3.75 
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µg H1N1 antigen (compared with the usual 15µg in TIV), produced by 
GlaxoSmithKline in Dresden in Germany. Before the start of the vaccination 
programme in Sweden, a pilot study was conducted among healthy individuals 
and it revealed a 98% protection rate after only one dose of the adjuvanted 
vaccine [58]. It was therefore decided to give one dose to the healthy and two 
doses to individuals belonging to a risk group. The vaccination started in mid-
October and, according to the Stockholm report, 100% of Swedish risk-group 
persons had been vaccinated at the beginning of December. Of Sweden’s 9.4 
million inhabitants in 2009, 61% were vaccinated with the pandemic vaccine 
[59].  
Other vaccines were also used around the world; MF59 adjuvanted vaccines 
or monovalent, non-adjuvanted vaccines containing 15 µg of antigen.  
Antiviral therapy against influenza  
The M2 inhibitors amantadine and rimantadine block the surface ion channel 
M2 and have proved effective against influenza A, but, starting in 2005, 
resistance has spread and now almost all H3N2 strains are immune to the drugs. 
The M2 inhibitors do not work at all against influenza B.  
Neuraminidase inhibitors act by blocking the NA which promotes virus 
release from the infected cell. As a result, the medication is unable to stop the 
viral assault and is only able to moderate the severity. There are two drugs, 
zanamivir and oseltamivir, which both reduce the duration of symptoms if 
introduced within 36 hours after the onset of symptoms. Resistance to these 
drugs has also been noted [15]. 
Adverse events and narcolepsy  
Unusual syndromes, such as Guillain-Barré syndrome, have been attributed to 
influenza vaccine. In 1976/77, a pandemic vaccine campaign was carried out 
in the USA as a result of fear of a new H1N1 influenza of swine origin. Four 
different vaccines were used, inactivated whole or split virus, mono or 
bivalent. During the six weeks following vaccination, a four- to seven-fold 
higher risk of Guillain-Barré was noted and it was attributed to the vaccination, 
although no particular vaccine or component could be identified [60]. 
The manufacturer of AS03-adjuvanted pandemic vaccine, GSK, has pooled 
data from all its studies of this adjuvant (in total, n > 22,000) and has found no 
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statistically significantly higher incidence of adverse events compared with 
non-adjuvanted influenza vaccine [61].  
The possible connection between Pandemrix® vaccination and narcolepsy in 
children and young adults has attracted a great deal of attention. The first 
reports came in June 2010 from Sweden, followed shortly after by Finland and 
subsequently from many European countries [62].  
Narcolepsy, a syndrome of hypersomnia with cataplexy (sudden loss of motor 
tone triggered by emotions) is caused by the selective destruction of hypocretin 
neurons. A genetic predisposition is seen; about 90% are carriers of the HLA-
DQB1*0602 alleles. This is, however, a very common allele (30% of Swedish 
and Finnish inhabitants) and an environmental trigger is needed. The 
suggestion is an autoimmune process, but no rise in inflammatory markers has 
been found. [63].  
The risk of narcolepsy was increased four to nine fold in Sweden and Finland 
after the Pandemrix® vaccination (manufactured in Europe, 30 million doses) 
but not in Canada, which used Arepanrix®, the same vaccine but manufactured 
in Canada by the same company (6.5 million doses). The calculated number of 
extra cases with the diagnose in Sweden during 2009-2011 were 136. 
Narcolepsy after PandemrixÒ vaccination was strongly correlated to the HLA-
DQB1*0602 allele and 94% of the cases had cataplexy. No other neurological 
disorder or autoimmune disease was overrepresented during the influenza 
pandemic in 2009 in Sweden. However, there was also an increase in the 
incidence of narcolepsy in China during the 2009 influenza pandemic, even 
though no vaccine was given, postulating the possibility of the H1N1 strain 
itself causing the disease. In fact, in an experimental study of mice lacking B- 
and T-cells, the mice developed a narcolepsy-like state and the virus targeted 
hypocretin-producing neurons [64]. For this reason, the cause of the high 
incidence of narcolepsy in 2009 has still not been fully elucidated.    
 
1.5 Hepatitis E virus (HEV) 
HEV is a small (27-32 nm), non-enveloped, single, positive-stranded RNA 
virus classified in a virus family of its own, the Herpeviridae. The virus is 
resistant to heating at 56°C for one hour but susceptible to boiling and frying 
for five minutes and to chlorination.  
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The possibility of another virus resembling hepatitis A was first recognised by 
dr MS Khuroo during a large epidemic in Kashmir Valley in 1978 when about 
52,000 individuals developed icteric hepatitis, causing the death of 1,700 
persons [65]. A faecal-oral route of transmission was established, due to 
contaminated water. HEV was first identified by electron microscopy in 1983 
in an experiment in Moscow where a suspension of stools from nine 
individuals with known active non-A-hepatitis was inoculated orally into a 
healthy volunteer (a Russian virologist) who developed hepatitis after 35 days 
[66].  
Today, in the light of effective vaccine against hepatitis A, HEV is considered 
by the WHO to be the major cause of acute hepatitis of viral origin in the world. 
It estimates 20 million HEV infections globally per year, 3.3 million with 
symptoms, and 56,000 deaths.  
1.5.1 Epidemiology 
Four genotypes infecting humans are known; HEV1-HEV4. HEV1 and HEV2 
appear in developing countries where they are endemic, causing epidemic 
outbreaks with a seasonal pattern. HEV1 is mostly found in Asia, Africa and 
Latin America, while HEV2 is found in Mexico and West Africa.  
HEV3, found in industrialised countries throughout the world, and HEV4 
(China, East Asia, Central Europe) cause sporadic cases. HEV3 and HEV4 
have a zoonotic reservoir, as they have been found in a number of different 
animals such as domestic pigs, wild boar and deer which can transmit the 
disease to humans [67]. Other routes of transmission are via blood products 
[68, 69] and, in fact, via transplanted organs, as found in two case reports [70, 
71] (Fig. 9). 
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The number of new HEV infections reported to Swedish health authorities in 
2015 was 29 cases. However, it has recently been shown that HEV3 is endemic 
in Sweden, with a prevalence of HEV-RNA in 10% of hunted wild animals 
[72] and positive anti-HEV IgG among 16% of healthy blood donors [73]. In 
1997, the seroprevalence in Sweden was 2-7.5%, depending on age [74], but 
today’s higher prevalence is not due to a higher incidence but to the 
improvement in serological assays [73]. This was shown in the Netherlands, 
where the seroprevalence almost 20 years ago was 0.4%, but a re-analysis of 
stored sera from 1988 revealed that the true prevalence was 46% [75]. There 
are regional differences in HEV3 prevalence in Europe as well. HEV3 is most 
common in the south of France, but prevalence numbers are otherwise very 
difficult to interpret, as they are dependent on the diagnostic tools.  
1.5.2 HEV diagnostic tools 
HEV serology (IgG and IgM) has typically been used as a diagnostic tool and, 
today, sensitive instruments are finally available [73]. Anti-HEV IgM is a 
marker of acute infection, while anti-HEV IgG can be seen in both acute and 
chronic or healed hepatitis. Quantitative PCR of HEV-RNA is a definite 
Figure 9.  Routes of transmission of HEV in the industrialised world.  Reprinted 
with permission from Viruses 2016 Sep 20;8(9). Khuroo MS et al.” Transmission 
of Hepatitis E Virus in Developing Countries”.  
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marker of viral replication, usually analysed in serum. A positive faecal test 
indicates that the individual is able to transmit disease.  The presence of HEV 
in urine is much less well known. In one report from China, urine HEV-RNA 
was positive in three of eight patients with acute HEV infection [76]. In another 
report from France, one in 51 with acute HEV had HEV RNA in urine [77].  
Fig. 10 illustrates the typical diagnostic signs of acute versus chronic HEV 
infection.  
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Acute HEV The incubation period is usually four to six weeks, but it has been 
described between nine days and two months. Fever, anorexia, vomiting and 
jaundice then develop. A rise in liver enzymes is seen. Symptoms may last for 
two to four weeks. In developing countries, the disease has a mortality of 1%, 
if acute liver failure develops. In some of these countries a particularly high 
mortality rate is found among pregnant women affected by HEV2 (25%) [78]. 
In the industrialised world, the HEV infection is estimated to be symptomatic 
in less than 5% of those who seroconvert [79]. Two studies from Europe have 
retrospectively studied HEV-RNA in patients with acute liver failure (ALF). 
They found 10% and 5% respectively were HEV-RNA positive and, at the time 
of treatment, most cases were misdiagnosed as drug-induced ALF. Most of 
these patients survived, but two underwent liver transplantation and one died. 
[80, 81]. 
Figure 10. The typical development of HEV specific IgM- and, IgG-levels and 
possible HEV-RNA detection during acute (A) and chronic (B) HEV infection. 
Reprinted from Gastroenterology Vol. 142, Wedemeyer H, Pischke S, Manns M. 
“Pathogenesis and Treatment of Hepatitis E Virus Infection”. Page 1388-1397 
(2012) with permission from Elsevier 
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Chronic HEV In 2008, the first cases of chronic HEV infection were reported 
by Kamar et al. from the south of France [82]. They had identified 14 patients, 
liver or kidney transplanted, with acute hepatitis due to HEV. Eight of the 
recipients developed chronic hepatitis confirmed by liver biopsy with 
persistent HEV-RNA positivity and an increase in liver enzymes with a 
duration of > 6 months, meeting the definition of chronic disease. The same 
group also reported one renal recipient with liver cirrhosis due to HEV [83]. 
Since then, a number of case reports of chronic HEV have been published, 
almost all found among solid organ transplant recipients. In a retrospective 
study from France, three (1.45%) of 206 liver transplant recipients developed 
chronic hepatitis and were HEV-RNA positive. Furthermore, two of the three 
were HEV IgG positive before RNA detection, indicating a secondary HEV 
infection [84]. In terms of numbers, HEV appears to be a marginal finding. 
However, fatal cases are seen. In one case report, a liver transplant recipient 
developed liver cirrhosis 15 months post-transplantation and died of 
septicaemia. Retrospectively, the diagnosis of donor-derived chronic HEV 
infection had developed into a rapidly fibrosing liver disease [70].  
Extra hepatic manifestations A number of reports have identified 
neurological manifestations secondary to HEV. The first case was reported 
from India; a patient with Guillain-Barré syndrome (GBS) together with acute 
HEV infection [85]. In the Netherlands, 5% of patients with GBS had an 
association with acute HEV infection, as they were IgM positive, three were 
also HEV-RNA positive but none had RNA in their cerebrospinal fluid (CSF) 
[86].  A number of case reports of encephalitis, some with RNA positivity in 
the CSF, are also worth noting [87]. Renal involvement is also described, but 
there are fewer cases and almost all were reported from Toulouse. In a series 
of 51 SOT recipients with an acute HEV infection, 57% developed a chronic 
HEV infection. Of them, five had a marked elevation of proteinuria, four had 
cryoglobulinemia and were kidney biopsied, interpreted as 
membranoproliferative glomerulonephritis in two. However, the proteinuria 
and cryoglobulinemia disappeared after treating HEV [77].  
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1.5.4 Treatment of HEV in SOT recipients 
Reduction of the immunosuppression is sometimes sufficient to attain viral 
clearance. This is in fact supported by in-vitro data, where HEV replication 
was stimulated by CNI but inhibited by MPA [88].   
Antiviral therapy might nevertheless be needed. Ribavirin monotherapy is the 
most frequently used. In one series from Toulouse, the sustained viral response 
at six months after three months’ treatment was 78% (n=59) and, after 
prolonged treatment, 85%. Interferon has only been used in a few cases but 
with 100% clearance of virus. Due to the risk of triggering rejection, interferon 
can only be used in liver transplant recipients [89]. 
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2 AIM 
The overall aim of this thesis was to study new viral infections among the 
immunocompromised, SOT recipient cohort and the effect of vaccination; one 
of our most important tools for protecting our patients from harmful viruses 
and other microbes.  
2.1 H1N1 vaccine studies 
The specific aims were:   
To analyse the H1N1/09 antibody response to the 
monovalent, AS03-adjuvanted influenza A H1N1/09 vaccine 
in SOT recipients compared with healthy controls 
To explore both the persistence of H1N1/09 antibodies one 
year after immunisation with the AS03-adjuvanted vaccine 
and the immune response after a booster dose with seasonal 
trivalent inactivated vaccine 2010 (TIV/10) containing a 
H1N1/09 component 
To identify adverse events due to these vaccinations using a 
questionnaire and chart review 
To investigate whether the influenza H1N1/09 vaccine 
triggers the production of de-novo HLA antibodies and 
rejection after vaccination 
To describe the graft function and incidence of rejection 
during the five years following the vaccination. 
2.2 HEV study 
The specific aims were:  
To investigate the prevalence of hepatitis E IgG and IgM 
among SOT recipients at the time of transplantation in 
Sweden compared with healthy blood donors 
To describe the incidence and clinical outcome of primary or 
secondary HEV infection in SOT recipients during the first 
two years after transplantation.  
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3 PATIENTS AND METHODS 
All the patients were recruited at the Transplant Institute, Sahlgrenska 
University Hospital, Gothenburg, Sweden. The H1N1/09 vaccine cohort is 
studied in Papers I-III and the hepatitis E cohort in Paper IV. 
3.1 H1N1/09 vaccine studies (Papers I-III) 
3.1.1 Subjects and study design  
The vaccination programme against the H1N1/09 influenza started in mid-
October 2009 and all SOT recipients were considered for vaccination, unless 
they were newly transplanted within the past month. A total of 82 SOT 
recipients from the outpatient clinic at the Transplant Institute, Sahlgrenska 
University Hospital, were included, as well as 28 members of the staff as 
healthy controls in the first study (Paper I). The subjects were vaccinated 
according to the Swedish guidelines with two doses of the monovalent, AS03-
adjuvanted vaccine, Pandemrix®. The second dose was administered three to 
four weeks after the first. Blood samples were drawn before both the first and 
second vaccine dose and a third sample was taken one month after the second 
vaccination to measure the serological response to the vaccine. 
The serum samples were re-analysed in those subjects who had both a baseline 
serum sample and a sample two months after the pandemic vaccination in order 
to study the HLA-antibody responses after the vaccination. Those who could 
be included in this analysis were 67 SOT recipients and 20 healthy controls 
(Paper III). 
In the follow-up study, one year later (Paper II), all the participants in the 
primary study were asked by mail to participate. A total of 49 SOT recipients 
and 11 healthy controls agreed. A single dose of TIV/10, Fluarix®, containing 
an H1N1/09 component, was administered. Serum samples were drawn before 
the vaccination and one month later for the analysis of anti-H1N1/09 antibody 
persistence and to see whether TIV/10 boosted the H1N1/09 antibodies. The 
patient populations in paper I-III are presented in Fig. 11. 
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At the time of both the first and the second vaccine studies (Papers I and II), 
the patients received a questionnaire to report side-effects.  
The medical charts of the SOT recipients were reviewed stepwise in Papers I-
III until five years after the vaccination, with regard to influenza symptoms, 
patient survival, graft function, renal function (measured glomerular filtration 
rate; mGFR), performed organ biopsies, rejection and rejection treatment. The 
database at the Laboratory of Virology was searched for any positive 
nasopharyngeal PCR tests for H1N1/09 between October 2009 and December 
2011. In Paper III, “Pro-inflammatory events”, as defined by Locke et al. [90] 
were also noted, i.e. infections, surgery, trauma or blood transfusion one month 
before vaccination until the last serum sample after the pandemic vaccination 
was drawn. 
Figure 11.  The patient population in Paper I-III 
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3.1.2 Vaccines  
The influenza H1N1/09 vaccine used in Sweden was Pandemrix® 
(GlaxoSmithKline, Dresden, Germany), an inactivated split influenza virus 
vaccine, containing antigen equivalent to the A/California/07/2009 (H1N1) 
derived strain (NYMC X-179A): 3.75 µg and AS03 adjuvant composed of 
squalene (10.69 mg), DL-α-tocopherol (11.86 mg) and polysorbate 80 (4.86 
mg). The vaccine was administered by an intramuscular injection into the 
deltoid muscle.   
A subset of the subjects (eight SOT recipients and one control) received one 
dose of trivalent seasonal influenza vaccine 2009 (TIV/09) Fluarix® 
(GlaxoSmithKline, Brentford, United Kingdom) between the second dose of 
Pandemrix® and the third serum sample. Another five recipients and one 
control received TIV/09 after the third sample. The TIV/09 contained 
A/Brisbane/59/2007 (H1N1) alike strain (IVR-148): 15 µg, 
A/Brisbane/10/2007 (H3N2) alike strain A/Uruguay/716/2007 (NYMC X-
175-C): 15µg, and B/Brisbane/60/2008 alike strain: 15 µg. 
In 2010, all the participants received the trivalent inactivated influenza vaccine 
(TIV/10) Fluarix® (GlaxoSmithKline, Brentford, United Kingdom) containing 
the A/California/7/2009 A(H1N1)pdm alike strain (NYMC X-181): 15 µg, 
A/Perth/16/2009 (H3N2) alike strain (NYMC X–187, derived from 
A/Victoria/210/2009):15 µg and B/Brisbane/60/2008: 15 µg. The vaccine was 
administered intramuscularly into the deltoid muscle. 
3.1.3 Haemagglutination inhibition assay (Papers I, II) 
Pre- and post-vaccination samples were analysed simultaneously by 
haemagglutination-inhibiting antibody assays (HAI) as previously described 
[91].  Briefly, the HAI was performed with 0.5% hen erythrocytes and 4 
haemagglutination (HA) units of virus (A/California/7/2009 NYMC X-179A 
H1N1). Sera were tested in serial twofold dilution steps at an initial dilution of 
1:10 to 1:640. The HAI titre was judged as the reciprocal of the last dilution 
that inhibited HA. Titres of ≥1:40 were considered to be a positive antibody 
response and protective against influenza. 
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 HLA typing and HLA antibody analyses (Paper III) 
Prior to 1993 the HLA-A, -B and -DRb1 loci of patients and donors were typed 
by serology (L. Rydberg, personal communication). Then, first Class II (HLA-
DRb1 and -DQb1) and since 2007 also Class I (HLA-A and -B) of patients and 
potential donors were molecularly typed on genomic DNA using either 
polymerase chain reaction (PCR)-sequence-specific oligonucleotides (SSOs) 
(LABType®; One Lambda, Inc., Canoga Park, CA, USA) or PCR-sequence-
specific primers (SSPs) (Olerup SSP®; Olerup SSP AB, Saltsjöbaden, 
Sweden), as described by the manufacturers. 
HLA antibodies Serum samples were drawn at baseline and three to four 
weeks after the second H1N1/09 vaccination. All the samples were analysed 
simultaneously, screening for HLA ab by LABScreen Mixed® (One Lambda 
Inc., Canoga Park, CA, USA) detecting Class I and Class II anti-HLA 
antibodies. In the event of a positive screening result, pre- and post-vaccination 
sera were further analysed for HLA antibody specificity (HLA-A, HLA-B, 
HLA-C, HLA-DR, HLA-DQa and b) using the LABScreen®Single Antigen 
assay (One Lambda Inc.), according to the manufacturer’s instructions. The 
test results were analysed using HLA Fusion 2.0.0 software (One Lambda 
Inc.). A positive result was defined as a mean fluorescence intensity (MFI) of 
≥ 1000. Donor specific antibodies were defined on the antigenic level. In cases 
where the donor was not HLA typed on all loci, non-typed loci were when 
possible inferred by genetic linkage to typed loci. Also, reactivity against 
HLA-DQA1, HLA- DPA1 and HLA-DPB1 could not be considered if DSA or 
not since we were not able to retype the donors. 
Crossmatch Before transplantation, all the patients underwent a CDC 
crossmatch. At our centre, all organs except livers are allocated to recipients 
with a negative CDC crossmatch. Liver transplantation is carried out 
disregarding the CDC crossmatch result, but, in this study, all liver-transplant 
recipients were CDC crossmatch negative at the time of transplantation. 
3.2 HEV study (Paper IV) 
3.2.1 Subjects and study design  
Adult organ transplanted recipients at the Transplant Institute, Sahlgrenska 
University Hospital, Gothenburg, Sweden receiving an organ between 2008 
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and 2009 were asked to participate in a study primarily designed for the 
detection of DNA viruses. A total of 227 patients were included. At the 
transplantation samples of whole blood, serum and urine were collected and 
thereafter monthly during the first six months, followed by every third month 
until two years post transplantation. The samples were transported to 
Sahlgrenska from the different outpatient clinics in our region and frozen for 
later analysis. Clinical data were collected from the Transplant Institutes 
quality database and from medical chart reviews.  
In a study conducted at Sahlgrenska University Hospital in 2015, 500 healthy 
blood donors were investigated regarding the prevalence of HEV infection 
[73]. These data were used in comparison with the SOT populations results 
analysed by the same assays 
3.2.2 HEV antibody detection  
Anti HEV IgM and IgG were detected simultaneously by a commercial 
enzyme-linked immunosorbent assay (ELISA) DiaPro (Milan, Italy) according 
to the manufacturer’s instructions.  A total of 432 sera from 196 patients were 
tested. An OD/cut-off value for IgM of ³ 1.5 and IgG of ³ 1.7 was considered 
positive. Furthermore, IgG ³ 1.2 to < 1.7 and IgM ³ 0.8 to < 1.5 were regarded 
as borderline reactivity. 
3.2.3 HEV RNA detection by real-time PCR  
All serum samples with a positive or borderline result of anti-HEV IgM and/or 
IgG were also analysed for HEV-RNA by real-time qPCR, all steps described 
in detail in Norder et.al. [73]. The RNA was extracted by using the components 
by NucliSENS easyMag; bioMérieux SA, France according to their 
instructions. Real-time PCR was performed on 20 µL of extracted RNA in 30 
µL of master mix. Cycling conditions were performed as described in [92]. 
One serum sample with HEV RNA and a known amount of a plasmid with 
cloned HEV sequences were used as a control in each assay. Based on the 
results obtained for the plasmid, the sensitivity of each assay ranged from 5 to 
10 copies of HEV RNA.  
3.3 Statistical analysis (Papers I – IV) 
Papers I and II: Fisher’s exact test was used to compare SOT recipients and 
controls with respect to protective antibody titres (≥1:40), side-effects, gender 
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and age (< or >60 years) (Papers I and II). Moreover, in the SOT recipient 
cohort, the correlation between protective titre versus mGFR (< or > 30 ml/min 
and KDOQI chronic kidney disease stages 1-5) and the type of transplant was 
analysed using this method (Paper II). A t-test was used to compare the mean 
antibody titres between the two groups. Analysis of co-variance (ANCOVA) 
adjusted for the effects of age and gender was used to correct for these group 
differences (Paper I). McNemar’s test was used for a comparison of the 
proportion of responders after the first and second H1N1/09 and TIV/10 
vaccine dose (Papers I and II). Wilcoxon’s two-sample test was used to 
compare the median titre value after the TIV/10 booster dose in SOT recipients 
and controls (Paper II). Pearson’s correlation coefficient was used to measured 
correlations between titres and the different immunosuppressant (Paper II).  
Papers III and IV: Fisher’s exact test was used for categorical data, while 
continuous data were analysed with paired and unpaired t-tests. Logistic 
regression models were used in Paper III when analysing the renal transplant 
cohort to find possible factors causing graft loss (time from transplantation and 
vaccination, pre-vaccination rejection, HLA, DSA, mGFR, difference mfi > 
1,000) and in Paper IV whether HEV IgG was dependent on age, gender or 
transplanted versus blood donor and type of organ transplanted. There is a need 
to interpret the regression analyses with caution due to the very small number 
of observations and possible confounding factors, particularly in Paper III. 
All: p-values of < 0.05 were considered to be statistically significant. The 
analyses were performed using SAS software, version 9.1. 
3.4 Ethical approval (Papers I – IV) 
All the studies were approved by the Regional Ethical Review Board in 
Gothenburg. Papers I-II: Reference number 590-10. Paper III numbers 590-10 
and T368-1. Paper IV: Reference number 150-08 plus T802-16. The separate 
study of blood donors, already published, had reference number 737-12. 
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4 RESULTS AND DISCUSSION 
4.1 H1N1 vaccine studies (Papers I-III) 
4.1.1 The patient cohort (Papers I-III) 
The majority of the patients were kidney transplanted and there was a tendency 
towards fewer women (Papers I-III: 43%; 51%, 46% respectively). The healthy 
controls were younger and most of them were female (Table 1). Among the 
included patients, five were vaccinated within three to nine months after 
transplantation, but four of them still developed a protective H1N1 antibody 
level after the pandemic vaccination. One liver recipient was re-transplanted 
before immunisation with TIV/10 due to chronic rejection which began before 
the H1N1/09 vaccination. Another liver transplanted patient with biliary 
complications at the time of enrolment was re-transplanted during the month 
between TIV/10 administration and the follow-up sample. Both these patients 
responded well to the H1N1/09 vaccine, had protective titres one year later, 
but the latter had a lower titre after TIV/10.  
 
Paper… SOT 
 
Organ transplanted 
% of total 
Year 
since 
SOT 
Control 
 n= Ktx Ltx Htx Com
-bi1 
Other2 Tx 
Median 
Age 
Median 
n= Age 
Median 
Paper I 82 60 20 8.6 7.4 3.7 6 60 28 43 
Paper II 49 55 26.5 8.2 10 0 7 59 11 42 
Paper III 67 67 21 4.5 4.5 3 6 57 20 48 
Ktx= kidney transplanted, Ltx=liver transplanted, Htx= heart transplanted. 1 Liver-kidney, heart-
kidney, liver-lung. 2Lung and limbal (corneal) stem cell transplantation. Tx = transplantation 
 
The immunosuppressive treatment was dependent on the transplanted organ; 
renal transplanted patients were most often on triple immunosuppression, 
while two drugs were more common if the patients were liver and heart 
transplanted. Around 10% were on monotherapy. About 90% of the recipients 
were on one CNI, often in combination with MPA and/or steroids. Anti-
rejection therapy was given to seven SOT recipients up to 14 months (three 
Table 1. A summary of some basic demographics of the SOT recipients and 
healthy controls in the vaccine studies (Paper I-III). 
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within six months) before the pandemic vaccination treated with ATG and 
plasmapheresis in two, otherwise only a course of steroids. Four of the seven 
responded with protective titres. During the two-months duration of the 
pandemic vaccination study, the immunosuppression remained unchanged, 
except for one individual who was put on low-dose CNI and low-dose 
everolimus due to low renal function. During the following period until one 
month after the TIV/10 vaccination, five patients had changed 
immunosuppression, (three weaned off steroids, one lowered MPA dose and 
one due to re–transplantation liver).  
Renal function was measured (51CrEDTA or Iohexol) in all but five SOT 
recipients in whom the estimated GFR (eGFR) according to the MDRD 
equation was used instead. The median GFR during the pandemic vaccination 
was 50 ml/min/1.73m2 (range 7-100) and, a year later, 47 ml/min/1.73m2 
(range 9-110). A GFR of less than 30 ml/min/1.73m2 was found in 23% and 
20% in Paper I and II respectively. In Paper III, when focusing on the different 
organ transplants, mGFR was 39 (range 7-100) among the renal transplanted 
patients and, among the other organ transplanted patients, the median was 60 
(18-100) ml/min/1.73m2 (the latter including five recipients with eGFR). 
4.1.2 H1N1/09 pandemic vaccination (Paper I) 
The AS03-adjuvanted vaccine was extremely effective in the healthy control 
group, where 96% reached a protective titre after one dose and 100% after two 
doses (Fig.12). This protection rate is in line with the findings in a population-
based study from Stockholm which, also among one million vaccinated 
individuals, found only 25 persons with vaccine failure [55]. The high 
protection rate among healthy persons has been reported by many [93, 94]. A 
Norwegian study of the seroresponse among 200 health-care workers found 
that 78% had protective titres after just one week and 98% three weeks after 
one dose of AS03-adjuvanted vaccine [95]. 
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Among the organ transplanted recipients, the responsiveness was lower 
compared with the healthy individuals, 69% after the first dose, while, after the 
second vaccine dose, 80% reached a protective titre (p=0.006 and p=0.003 
respectively) (Fig. 12). There are four other studies of the AS03-adjuvanted 
influenza vaccine in an SOT population and three of them used only one 
vaccine dose. Those who gave one dose report a seemingly significantly lower 
seroprotection rate compared with ours; 34%-44%, all in kidney transplanted 
patients [96-98]. The substantially lower vaccine responses reported in these 
studies may depend on different immunosuppression and vaccination 
performed at various times after transplantation. In contrast, our findings are 
comparable with those in the study by Siegrist et al. investigating 202 SOT 
recipients and 131 controls [99]. After two doses, they found an overall 
response rate of 70.3%, but, in kidney, liver or pancreas transplanted 
individuals, the rate was > 80%. Lung transplanted patients (n=25) had a 
significantly lower response (43.6%). Unfortunately, they did not have data on 
serostatus after only one dose.  
Figure 12. The percentage of Sot recipients/healthy controls with a protective 
titre against H1N1/09 after vaccination with the monovalent AS03-adjuvanted 
influenza vaccine 2009 (n=82/28), serostatus one year later and the subsequent 
reaction after a booster dose of TIV/10 (n=49/11). Only significant titre 
differences are noted in the figure. 
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The magnitude of anti-H1N1/09 titre rise was significantly higher among the 
healthy controls; after two doses of the AS03-adjuvanted vaccine, the median 
titre was 1:640 compared with the SOT recipients’ median of 1:80 (p<0.001), 
(Fig. 13). A comparable difference was noticed by Siegrist et al., who found a 
threefold lower titre among the SOT recipients [99].  
At study start, three SOT recipients and two healthy controls (4.6%) had a 
protective titre (1:40) against influenza A H1N1/09 (Fig. 12). A Swedish 
survey published in 2012 conducting a re-analysis of sera from 2007 found 
HAI titres of ³ 1:40 among 4.5% in the Swedish population, even higher at 
ages ³ 80 years (9.3%) [100]. An analysis of the H1N1 three-dimensional HA 
structure from 1918 and 2009 shows that they are alike, older individuals 
probably have a partly immunological memory of the Spanish flu [101]. 
However, in the younger cohort, the seropositive reactions are presumably due 
to cross-reactive antibodies from earlier seasonal H1N1 influenza. The same 
has been found elsewhere; in a meta-analysis from a number of studies around 
the world of the pre-pandemic H1N1 antibody status, the overall 
seroprevalence was in fact 5%, with a lower prevalence among younger 
persons and a rising incidence with increasing age [102]. Some regional 
differences were seen and the authors speculated that this was possibly due to 
assay sensitivity differences. This has been reported by others and there is no 
standardised method for influenza antibody detection. According to a WHO 
meeting report evaluating the influenza pandemic in 2009, significant 
differences have been seen when comparing the HAI assay result between 
laboratories [94]. Those three recipients with a protective titre before the 
H1N1/09 had a one-, two- and four-fold titre rise respectively, perhaps a less 
prompt vaccine response than expected. One peculiar finding reported by some 
authors is that TIV administered one to two years before the pandemic 
vaccination might lower the response to the pandemic vaccine [103, 104]. This 
is the opposite reaction to what could be expected; a booster effect is usually 
seen after repeated vaccinations. However, in this situation, the antigens used 
differ between the vaccines. As a result, different TIV vaccination histories 
might be another factor explaining the discrepancies between the above-
mentioned reports. 
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4.1.3 Antibody persistence one-year after H1N1/09 
pandemic vaccine (Paper II) 
There was a significant loss of protective titres 10-14 months after H1N1/09 
vaccination. Among the SOT recipients 23/49 (47%) had protective titres 
compared with 80% directly after vaccination (p=0.02). The corresponding 
numbers for the control group were 7/11 (63%), compared with (100%) the 
year before (p=0.008), (Fig. 12). Looking at SOT populations, two studies have 
been published on the loss of the antibody protection one year after using the 
H1N1/09 vaccine. Cordero et al. [105] reported a decline in protection from 
80% to 30% over one year; seemingly a more profound drop than in our study. 
In that study, only one dose of MF69-adjuvanted monovalent vaccine was 
administered (Table 2). To some extent, this could account for the lower 
remaining immunity in their cohort of recipients. Siegrist et al. [106] is the 
only study using two doses of AS03-adjuvanted influenza vaccine, as in our 
study (Table 2). They found that 67% of the kidney transplant recipients had 
protective titres one month after immunisation. In contrast to our study, they 
did not detect a loss of protection, as 65% continued to have HI titres of ≥ 1:40 
one year after vaccination. There is no obvious explanation of this difference 
Figure 13.  This boxplot shows the distribution of anti-H1N1/09 antibody titres from the 
start of the pandemic vaccination until one month after the following year’s TIV/10 
vaccination. The box represents the 25th-75th percentile, the dark line represents the 
median and the extended bars represent the 10th-90th percentile. Asterisks and rings 
represents outliers. 
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when compared with our study, as they studied renal recipients with a 
comparable age, immunosuppression, time after transplantation and renal 
function. Among healthy individuals one year after two doses of AS03-
adjuvanted pandemic vaccine, the seroprotection rate was 79.1% at ages 18-60 
years and 54.4% if above 60 years [107]. We did not find an age effect, perhaps 
due to the small number of subjects. In healthy children and a corresponding 
vaccine regimen, 98% had remaining seroprotection after one year compared 
with 51.6 % of the children receiving non-adjuvanted, whole-virion 
monovalent vaccine illustrating the different immune responses to different 
pandemic vaccines [108].   
4.1.4 TIV/10 booster dose (Paper II) 
Boosting with TIV/10 enhanced the immune response to H1N1/09 in our SOT 
recipients to some extent, albeit not significantly. In particular, the frequency 
of responders increased from 49% to 71% (p= 0.2) as compared with 100% 
among the healthy controls (p=0.05), (Fig. 12). Three other studies have also 
shown a booster effect with TIV/10 among organ transplant populations (Table 
2). In these studies, the seroprotection rate after TIV/10 vaccination varied 
between 53% and around 80% [105, 106, 109]. The lower frequency (53%) of 
responders reported in the study performed by Mulley et al. [109] may reflect 
the low baseline titres after a single dose of non-adjuvanted H1N1/09 
vaccine.  The distribution of the magnitude of the H1N1/09 antibody titre rise 
after boosting with TIV/10 is shown in Fig. 13. The median titre increased 
from 1:20 to 1:80 in the SOT recipients and from 1:80 to 1:640 among the 
controls. The titre rise was significantly lower among the SOT recipients when 
compared with the controls (p=0.004).  
 Felldin et al. 
[110] 
Siegrist et al. 
[106] 
Cordero et al. 
[105] 
Mulley et al. 
[109] 
Patients SOT n=49 Kidney tx n=53 SOT n=96 Kidney tx n=49 
Vaccine AS03 2 doses AS03 2 doses MF59 1 dose Non-adjuv 1 dose 
Pre H1N1/09  3.6% 13.4% 13.6% 13% 
Post H1N1/09 79% 67.3% 83.9% 34.7% 
Pre TIV/10 49% 66% 30% no data 
Post TIV/10 71% 72% 79% 53.1% 
Table 2. Comparison of percentage seroprotection (titre ³40) between four 
studies of TIV/10 booster effect in SOT populations 
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4.1.5 Non-responders (Papers I and II) 
Some patients did not develop a protective antibody titre after vaccination; in 
Paper I, 15.8% and, in Paper II, 28.6%. As a result, these patients were “non-
responders” to the pandemic vaccine and the H1N1/09 component of TIV/10 
respectively. The non-responders did not differ significantly in terms of age 
when compared with responders in our studies. In the comparable but larger 
study (n=202) after the pandemic vaccine by Siegrist et al. [99], an 
independent risk factors for non-responsiveness was in fact higher age, as also 
shown by Mulley et al. [109]. Since age is usually a dependent factor for 
seroresponse in vaccine studies, our studies might have been under-powered 
in this respect.  
In both Study I and II, non-responders were more often treated with triple 
immunosuppressive therapy compared with responders [92% vs 35% and 79% 
vs 34% respectively]. Moreover, we were also able to show in Paper II that 
93% of the non-responders were treated with MPA compared with 48.6% of 
the responders (p=0.0006). This is in line with others who found that MPA 
treatment reduced the likelihood of achieving seroprotection after H1N1/09 
vaccination in a dose-dependent manner [96, 99, 109]. Interestingly, Siegrist 
et al. found that, after the pandemic vaccination, if the MPA trough level was 
³ 4µg/mL, the response was reduced by 80% [99]. In their follow up study 
after the TIV/10 booster dose, MPA-treatment only tended to have an impact, 
but this cohort was much smaller (Table 2) [106]. 
A decreased response was seen in our patients with severe renal impairment. 
If renal function was better (mGFR ≥30 mL/min/1.73m2), 87% responded with 
protective antibody titres after the pandemic vaccination, compared with 61% 
of patients with a GFR of < 30 (p=0.036) and this was also a significant factor 
for the response after the TIV/10 booster dose (p=0.003). The same finding 
was made by others [109]. In contrast, Dikow et al. found a good immune 
response to H1N1/09-adjuvant vaccine in a haemodialysis population [111] 
and, in the multivariate analysis of the response to the pandemic vaccine by 
Siegrist et al., renal function was not an independent risk factor, while age and 
MPA treatment were [99].  
4.1.6 Adverse events after vaccination (Papers I and II) 
Side-effects At the time of the administration of the first pandemic vaccine 
dose and TIV/10, a simple questionnaire was given to all subjects to be 
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returned two to three months later. We asked about the most common 
symptoms after vaccination (Table 3) and if there were “other symptoms”. The 
response rate was 93% and 75% in the SOT cohort in the first year and second 
year, while it was 96% and 100% respectively in the control group. A tendency 
was found among the healthy controls towards a stronger experience of muscle 
pain (Table 2). Another study also comparing with healthy controls reported 
less frequent local symptoms in the SOT population [99].  
 
 
Patients  Controls 
Reported symptoms  
n= (%) 
H1N1/09 
1st dose 
H1N1/09 
2nd dose 
TIV/10 H1N1/09 
1st dose 
H1N1/09 
2nd dose 
TIV/10 
Local symptoms1 51 (68) 41 (55) 8 (21) 16 (59) 12 (44) 4 (36) 
Muscle pain  16 (21) 15 (20) 7 (19) 13 (48)2 12 (44)3 3 (27) 
Fever 10 (13) 13 (17) 2 (5.4) 8 (30) 6 (22) 0 
Cough 4 (5) 3 (4) 4 (11) 1 (4) 1 (4) 0 
Headache 2 (3) 4 (5) 1 (2.7) 4 (15) 4 (15) 0 
       
1Tenderness, redness and pain at the site of injection, 2p=0.01, 3p=0.02 
 
Adverse neurological events In our cohort, one patient experienced 
vertigo and one developed unilateral deafness after the pandemic vaccine. 
There is a single report of sudden deafness, a healthy teenager after the vaccine 
[112]. There have been no reports of narcolepsy after the H1N1/09 vaccination 
among SOT recipients. A meta-analysis performed in 2013 (not mentioning 
narcolepsy cases) compiled 104 reports of neurological complications in 1,349 
persons after the H1N1/09 pandemic influenza infection and 247 after 
vaccination. The influenza infection group did less well; 97% were children 
who developed encephalopathy, 4.7% died and 30.1% developed permanent 
sequelae. The vaccine group were mostly adults (72%) suffering from 
Guillain-Barré (64%) and they all survived [113].  
4.1.7 HLA antibody reaction (Paper III) 
No SOT recipient became HLA sensitised during the two months after the first 
dose of AS03 adjuvanted vaccine. Previous studies of de novo HLA antibody 
Table 3. Side-effects comparing H1N1/09 and TIV/10 among SOT recipients 
versus healthy controls 
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development in SOT populations after the same vaccine have reported 
diverging results. Our data are in agreement with the results presented by 
Broeders et al., who reported de novo HLA alloantibody formation in only one 
of 111 renal transplant recipients [97]. In contrast to our results, other studies 
have found a higher production of de novo HLA antibodies. Fairhead et al. 
reported that almost 12% of kidney transplant patients developed de novo HLA 
antibodies [98]. This is in line with the findings of Katerinis et al., who 
reported that 12-17% of renal SOT patients developed HLA antibodies after 
an influenza vaccination containing AS03 [114]. One possible explanation of 
the latter finding is that the majority of the patients received not only two doses 
of adjuvanted H1N1/09 vaccine but also one dose of TIV/09 prior to the 
H1N1/09 vaccine. It is possible that, the more intense the influenza vaccine 
regimen, the more frequent de novo HLA antibody formation. In our HLA 
study, only 8/67 patients and 1/20 controls were vaccinated with TIV/09 
between the second vaccine dose and the serum sample one month later. Most 
HLA antibodies in the Katerinis study were detected at low MFI (<2,000) and 
generally resolved by six months.  
At the start of the H1N1/09 vaccination, 26 of 67 (39%) of the SOT recipients 
had HLA antibodies which were detectable as compared to five of 20 (25%) 
healthy controls. When comparing demographic data, only the number of years 
since transplantation tended to be significant for the presence of HLA 
antibodies (p=0.03). 
HLA antibodies with new specificities were seen in seven (10.4%) SOT 
recipients, all of whom were HLA immunised before vaccination with 
antibodies against 16-52 Class I antigens and 0-6 Class II (Fig. 14). They had 
higher post-vaccination MFI values, in both in Class I and II, albeit not 
uniformly. Three of the seven recipients also had DSA before vaccination and 
these MFI values increased post-vaccination. Proinflammatory events were 
seen in three of our seven patients with new HLA specificities and these can 
influence the HLA reaction substantially (2.5-fold) as showed by Locke et al. 
in a cohort of immunised renal transplant recipients [90]. One of these three 
also received a blood transfusion, which also, although nowadays leukocyte-
reduced, have been shown to increase the HLA ab strength in patients on the 
waiting list [115]. 
Donor specific antibodies (DSA) No recipient developed de novo DSA 
after vaccination and no DSA disappeared. Of the 26 sensitised patients, 15 
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had DSA and 11 non-directed HLA antibodies before the pandemic 
vaccination. The change in the DSA MFI values after vaccination was not 
statistically significant when considering the strongest MFI value or the 
cumulative DSA. However, we are unable to preclude that some of the new 
specificities of HLA antibodies that were seen were in fact donor specific, as 
we were not able to re-type the donors. Furthermore, in 13/15 patients, all the 
DSAs were inferred by genetic linkage to typed loci. The occurrence of de 
novo DSA after the AS03 adjuvant influenza vaccination varies between 0-
8.8% in different studies [97, 98, 114]. Apart from clinical differences between 
these patient cohorts, the single antigen technique is not standardised and 
differences between centres could therefore also depend on the assay (with a 
LOT to LOT variation), the execution of the assay and the interpretation of the 
results including different cut-off values. 
 
             
	 ):9+'4*).754/)7+0+)9/54(Papers I-III)
In most studies, no increased risk of allograft dysfunction or clinical rejection 
has been reported and no acute rejection episode occurred in our study during 
the first two-year follow-up after the vaccination. Two recipients were 
diagnosed with chronic rejection but they had a lower or mixed DSA response. 
In those reports which found new HLA antibodies, single patients with de novo 
DSA have in fact developed acute or chronic AMR [96, 98, 114]. There are, 
however, possible causes other than the pandemic vaccine coinciding with the 
development of both DSA and rejection. Non-adherence or earlier 
Figure 14. The seven SOT recipients who developed HLA antibodies with new 
specificities after vaccination. Here represented by their HLA antibody with the 
highest MFI value in Class I and II. Three patients had both Class I and II HLA-
antibodies. 
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minimisation of the immunosuppression is thought to be the cause of many 
AMR and subsequent graft losses [116, 117]. 
4.1.9 Five-year clinical follow-up (Paper III) 
From the time point of the H1N1/09 vaccination, the overall one-, two- and 
five-year patient survival was 100%, 98.5% and 82%, and the corresponding 
overall graft survival was 94%, 88% and 80%, including graft loss due to 
deaths with no impact of HLA antibody status. Five-year graft survival among 
those seven recipients with HLA antibodies with new specificities was (57%) 
(p=0.8) and, among the 15 recipients with DSA, it was 46.6% (p=0.04).  
Among renal transplanted patients there was a correlation between the five-
year graft survival after vaccination with the presence of both DSA (p<0.0001) 
and low mGFR/09 (p<0.0001). In fact, in renal recipients with no DSA, the 
five-year graft survival was 83% in comparison with 22% in the DSA-positive 
group. There was a relationship between a rise in the DSA Class II titre at 
vaccination and graft survival at five years (p=0.001), but the impact of this in 
relation to the pre-existing lower renal function and DSA is questionable. By 
way of comparison, Lachman et al. re-analysed stored serum for HLA 
antibodies using the single antigen technique in 1,014 renal recipients 
transplanted in 1984-2004 and calculated the five-year outcome after the test 
was taken. The graft survival among the HLA negative recipients was 83%, 
but, in patients who were DSA positive in combination with an estimated GFR 
of < 30, the survival was only 12% [118]. 
4.1.10 Risk and benefit of H1N1/09 vaccination  
To summarise, the risk of both adverse events and HLA immunisation after 
H1N1/09 vaccination appears to be low and should be compared with the risk 
of the influenza disease. The pandemic H1N1/09 infection had a mortality rate 
among unvaccinated hospitalised SOT recipients in 2009 of 4% [56]. A more 
recent report from Finland highlights the need for continuous TIV vaccination. 
Due to the reports of negative side-effects after the AS03-adjuvanted 
vaccination, a lower adherence to seasonal vaccination recommendations 
developed in Finland. In the spring of 2014, an outbreak of influenza A H1N1 
occurred on the ward at the transplant unit in Helsinki. Of 23 patients, six had 
not been vaccinated with TIV/13, five developed symptomatic influenza 
disease and three of them died despite maximum ICU support. Those three 
were all newly transplanted (< 1 month).  Among the 17 who were vaccinated, 
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two tested positive for influenza and only one of them had mild symptoms 
[119]. This also points to the importance of vaccination ahead of 
transplantation, despite the knowledge of a lower seroresponse among 
individuals with end-stage organ failure. 
4.2 HEV study (Paper IV) 
4.2.1 The study population   
A total of 196 SOT recipients were followed with regular serum and urine 
sampling during the first two years after transplantation to establish the 
prevalence and incidence of hepatitis E virus infection. The prevalence was 
compared with corresponding data in 500 healthy blood donors [73]. A total 
of 375 serum and 346 urine samples from the SOT recipients were 
investigated. The median age among the kidney transplanted patients was 52 
years compared with the other SOT recipients, who had a median age of 45.5 
years and healthy controls, who were 44 years old. In both the study population 
and the healthy controls, fewer were women, 34.2% and 36.2% respectively. 
Most of the SOT recipients had received a kidney (59%), but they also included 
liver (20%), lung (12.7%) and heart (7.6%) transplants and one multivisceral 
graft. Renal recipients had a longer history of transplantation, as 20.5% 
received their ³ 2nd graft compared with the other SOT recipients (2.5%) 
(p<0.001). The immunosuppressive treatment was generally a combination of 
CNI, MPA and corticosteroids, with the exception of 16 liver transplanted 
patients who only had CNI plus steroids. Acute rejection episodes were seen 
in a total of 25% of the recipients; this was not always biopsy proven in non-
renal organ transplanted patients. 
 
4.2.2 HEV infection before transplantation 
In order to find those SOT recipients with previous, recurrent or de novo HEV 
infection most efficiently, the screening for anti-HEV antibodies was started 
with the serum samples at 9-15 months post transplantation but for 13 patients 
the last available sample was drawn at month 6. Further analyses were made 
in a stepwise fashion to identify when the infection occurred, before or after 
the transplantation (Fig. 15). 
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At the time of transplantation, 60/196 (30.6%) of the SOT recipients were HEV 
IgG positive, significantly more compared with 16.8% of the healthy blood 
donors (p<0.0001). There were no gender differences, no differences 
depending on type of organ transplanted or whether the patient received a first 
graft versus being re-transplanted. However, there was a strong correlation 
with age; the older both the healthy individuals and SOT-recipients were, the 
higher was the anti-HEV IgG prevalence (p<0.0001). Among the younger 
individuals (< 50 years), HEV IgG positivity was somewhat more frequent in 
the SOT cohort compared with the blood donors (p=0.04), but in fact, it was 
only 10 SOT recipients < 50 years old who were HEV-IgG positive. Seven of 
them were renal transplanted (four with unknown renal disease and three with 
former transplants) and one heart-, lung- and liver transplanted respectively. 
With increasing age, the difference disappeared and, when both blood donors 
and SOT recipients were older than 60 years, there was an even and high anti-
Figure 15. Results from analysing for anti-HEV IgM/IgG in sera from the SOT 
population starting at month 6-15. 1Sera drawn at month 18 and 24 from the two 
patients who were still IgM positive at 15 months.  = borderline value. 
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HEV prevalence in both groups;  47% and  respectively (p=0.7). The 
development of assays for anti-HEV IgG and IgM detection with both high 
sensitivity and specificity explains today’s higher anti-HEV prevalence figures 
overall [120]. Our SOT population has a seroprevalence that is almost as high 
as that found in the high-prevalence area of southern France, where 40% of the 
SOT population is HEV IgG positive [121, 122].  A recent study from Italy 
using the same assay as we use found a lower incidence among their blood 
donors (7%) and individuals with chronic liver disease (9.2%) with median 
ages almost comparable to our study (45.5 and 52.3 years respectively) [123]. 
They also had a cohort of patients with chronic renal disease with an anti-HEV 
prevalence of 30.7%, but they were significantly older (median 74.3 years) 
and, after adjustment, they found that only age, not kidney disease, was an 
independent risk factor for HEV IgG. As a result, the anti-HEV prevalence is 
unexpectedly high in Sweden and SOT recipients appears to be affected by 
HEV at an earlier age. The reason for this earlier onset is not known but it is 
probably due to a number of causes; persons with chronic disease run the risk 
of being infected via blood products [68, 69] or transplanted organs [70, 71]. 
Single patients with acute HEV infection might have been misdiagnosed [80]  
and speculatively, single cases of chronic renal disease might be caused by 
HEV [77]. Our finding with 4/10 younger HEV positive with unknown renal 
disease needs to be studied further.    
            
 
Figure 16. A higher proportion of SOT recipients were HEV-IgG positive 
compared with healthy blood donors (BD) at ages below 50 years. 
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4.2.3 HEV infection after transplantation 
In eight patients we found HEV IgM at the transplantation, indicating a recent 
infection before transplantation. Two of them continued to have high IgM 
levels throughout the follow-up (15 and 24 months respectively). All the tested 
samples were negative for HEV-RNA and the patients did not develop liver 
affection. Nevertheless, we are unable to rule out the possibility of chronic 
HEV infection in these two. Another two IgG- and IgM-negative patients 
seroconverted after transplantation and became HEV IgG positive at the 18- 
and 24-month follow-ups. No RNA could be detected in serum or urine at 
conversion or three to nine months before. This might be due to a primary HEV 
infection occurring during the follow-up after transplantation albeit with an 
indolent course. Another recipient, HEV IgG positive at the time of 
transplantation, had detectable HEV-RNA in a single urine sample one month 
post-transplantation but no signs of infection in other parameters. These five 
cases of possible new or chronic HEV infections are perhaps too few in an 
immunocompromised cohort, as 5/500 of the healthy controls were PCR 
positive in serum, all five with anti-HEV IgG, but only two had a borderline-
value of anti HEV IgM [73]. The reason only one sample had detectable HEV 
RNA might be explained by the handling of the study samples, as the study 
was not designed for RNA detection but for the detection of DNA viruses. 
However, the fact that we found HEV RNA in urine is interesting. One other 
study has reported HEV4 RNA in urine [76]. This indicated that urine could 
also be used to identify on-going infections. Compared with France, which saw 
HEV re-infection in 3.3% (3/263) and de novo infection during the first year 
after transplantation in 2.1% (all diagnosed by the detection of HEV RNA) 
[121], the number of cases we have identified, if correctly interpreted, are what 
would be expected in the context of our anti-HEV prevalence.  
Our patients did well and a decrease in immunosuppression could be enough 
to resolve HEV infections. In a compilation report of 85 SOT recipients with 
confirmed HEV infection, 65.9% developed chronic disease [124]. In 32.1% 
the infection resolved, eight developed liver cirrhosis and two needed a liver 
re-transplant. There are also case reports of rapidly fibrosing hepatitis due to 
HEV after liver transplantation [70] and it is therefore important to identify 
HEV infection at an early stage.  
In our view, the unexpected high prevalence of anti-HEV IgG among the 
Swedish SOT recipients in this study highlights the possibility of hepatitis E 
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as a new opportunistic infection in the immune compromised host and there is 
a need of further studies if, and to what extent HEV cause secondary organ 
involvement.  
  
68
 69 
5 CONCLUSIONS 
Paper I 
Vaccination with the monovalent AS03 adjuvanted influenza A H1N1/09 
vaccine was well tolerated and over all effective in SOT recipients although 
significantly less compared with healthy controls.  A second dose of the same 
vaccine enhanced the immune response significantly among the 
immunocompromised patients. 
Paper II 
One third of both SOT recipients and controls had lost their protective antibody 
level one year after vaccination. After a boosting dose of TIV/10, some of the 
SOT recipients regained seroprotection, while all the healthy controls returned 
to their former seroprotection levels. 
Paper I + II 
Vaccine non-responders had more often lover renal function (mGFR 
<30ml/min/1.73m2), triple immunosuppression and MPA-treatment.  No acute 
rejection was identified during the first two years after pandemic vaccination. 
Paper III 
No SOT recipient became HLA immunised between the start of the pandemic 
vaccination and two months later. In 10% of patients previously allo-
immunised, HLA antibodies with new specificities were seen. No de novo 
donor specific antibodies (DSA) were seen with the limitation of that no new 
donor tissue typing was possible. Two cases of chronic rejection diagnosed 
within one year of vaccination had a mixed DSA response and was probably 
unrelated to vaccination. A subgroup of renal transplant recipients had DSA 
and low renal function at study start and did very poor at long term follow up. 
Paper IV 
Hepatitis E virus have affected 30% of SOT population at the time of 
transplantation; a significantly higher prevalence compared with healthy, 
particularly in ages below 50 years. A suspicion of new and chronic HEV in a 
few patients during two years of follow up could not be verified by HEV-RNA. 
A single urine sample was HEV-RNA positive in a HEV-IgG positive patient 
one moth post transplantation. 
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6 FUTURE PERSPECTIVES 
The balancing act between rejection and infection is a challenge for all 
transplant physicians and the formula for achieving tolerance appears to be far 
off. The state of tolerance also appears to be vulnerable and could be 
challenged by vaccination. This became very clear to me when Dr. Mary 
Louise Market gave a lecture on thymus transplantation at the 2016 ATC 
Congress. One of her patients had been tolerant for 10 years but, after a measles 
vaccination, the tolerant state was lost within 14 days. This exemplifies the 
need for further research on vaccinology and clinical transplantation, apart 
from the very fundamental issue of basic transplant immunology.  
The rate of seroprotection after the AS03-adjuvanted vaccination was fairly 
good in our SOT population, but there are a number of non-responders who 
are in need of better protection. Higher vaccine doses or repeated vaccinations 
have been suggested [97], but alternative strategies [125], such as the more 
effective medical treatment of influenza, are needed. Studies testing 
monoclonal antibodies against conserved surface structures of the virus, such 
as the M2 ion channel (the antibody TCR-032) or the stalk of the HA molecule 
(VIS410, CR8020 and others) in particular, are in progress, even if there are 
obstacles that need to be removed before these drugs can be introduced into 
the clinic [126]. Our conclusion in Papers I and II was that the use of AS03-
adjuvanted vaccines in the SOT population was safe, as was concluded by 
Cordero et al. [105, 127] and Broeders et al.[97]. In contrast, those authors who 
have studied the HLA antibody reaction more closely argue that the vaccine 
effect needs to be further studied before we use it again, due to the risk of allo-
immunisation [96, 98, 114]. None of the current observational studies has fully 
elucidated the risk since they were not designed for this purpose. To address 
the question, a controlled study with both a larger and more uniform cohort of 
patients is needed. The optimal design would include an un-vaccinated 
(probably not feasible) or non-adjuvanted vaccine SOT control group. Both the 
serological and cellular immune response need to be studied, from the angle of 
both protection and immunisation. The diagnosis of rejection still relies on 
biopsies and, as a result, control biopsies would be needed, together with solid 
phase data and a long-term follow-up. However, due to the cases of narcolepsy, 
the AS03-adjuvant will probably only be used again if we are threatened by a 
particularly dangerous infection, not as an influenza vaccination. 
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Hepatitis E is a common form of hepatitis in Sweden, in particular among 
SOT recipients, but the infection is still unrecognised by us, the medical 
professionals. The reports of chronic liver disease, as well as extrahepatic 
manifestations among SOT recipients, highlight the need for a new awareness 
of HEV among hepatologists, nephrologist and neurologists in cases with 
unknown cause of organ disease or rapid decline in organ function. 
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